

2017/19 PbR Excluded Drugs: proposed GMMMG Advisory Position [Appendix 3]

Date of this document: April 2018. Updated in line with Annex A of National tariff payment system 2017/19 issued 22.12.16 (no changes to drug content required compared with V1.0 which was approved by GMMMG on 17th November 2016 and with reference to NHSE V13 spreadsheet dated 23/03/18.)	Commissioner category: C= CCG N= NHS England N*= expected to be NHSE but not on V13 s/sheet	Further notes available at foot of spreadsheet N.B. for NHSE-commissioned drugs, consult NHSE information for commissioning policy / position.	Note: many BNF Categories inserted using NDO on NHSE s/sheet where Annex C of NHSE s/sheet says "none" or "n/a"	Group: A group includes all drugs in that group regardless of specific drugs listed. Individual - This is for the specific listed drug only	Drugs in blue cells are new additions for 2017/19. Probable commissioner indicated	Highlighted cells are amendments made to 2016/17 version	Highlighted cells in this colour are amendments made to 2017/19 version for 2018				For forthcoming new drugs, an expected time of availability is presented when stated by SPS but this may change in the future.
---	---	--	--	--	---	---	---	--	--	--	--

No.	Drug Name <i>(some brand names added for clarity in italics)</i>	Commissioner Category	PBR Category	BNF category (legacy)	Group	Indication	Prior Approval Category	Commissioning Policy Type	Commissioning Policy Link	Comments
1	Abacavir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
2	Abacavir with dolutegravir and lamivudine <i>Triumeq</i>	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				included to match NHSE list
3	Abacavir with lamivudine	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				included to match NHSE list
4	Abaloparatide	N	Drugs affecting bone metabolism	6.6.2	Individual	Male and juvenile osteoporosis				
5	Abaloparatide	C	Drugs affecting bone metabolism	6.6.2	Individual	Postmenopausal osteoporosis	Individual Funding			s/c injection; not in PO
6	Abatacept	N	Cytokine modulators	10.1.3	Group	Juvenile Idiopathic Rheumatoid Arthritis			http://gmmmg.nhs.uk/docs/subgroups/sbgrp-hcdsg/Child-to-adult-services-statement-amended-post-meeting.pdf	For children transitioning to adult services and becoming a CCG commissioning responsibility, category is monitored when in line with the referenced GMMMG guidance.
7	Abatacept	N	Cytokine modulators	10.1.3	Group	Paediatric indications (where adult TA available)		As per adult TA's (TA195, TA280)		
8	Abatacept	C	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis, after failure of conventional DMARDs	Monitored	NICE TA375 / GM Harmonised biologics pathway	http://www.nice.org.uk/guidance/ta375 http://gmmmg.nhs.uk/docs/guidance/GMMMG%20RA%20Pathway%2022%20april_2015.pdf	
9	Abatacept	C	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis, after failure of TNF inhibitor, if rituximab contra-indicated	Monitored	NICE TA195	http://guidance.nice.org.uk/TA195	
10	Actoxumab + Bezlotoxumab	C	Cytokine modulators		Group	Clostridium difficile infection -prevention of recurrence after 2nd+ episode	Individual funding			New 31.10.16 but SPS says development discontinued (actoxumab ineffective, development restricted to bezlotoxumab)
11	Abiraterone	N	Hormone antagonists	8.3.4.2		Cancer				included to match NHSE list

12	Adalimumab	N	Cytokine modulators	10.1.3	Group	Hidradenitis Suppurativa				http://gmmmg.nhs.uk/docs/subgroups/sbgrp-hcdsg/Child-to-adult-services-statement-amended-post-meeting.pdf	For children transitioning to adult services and becoming a CCG commissioning responsibility, category is monitored when in line with the referenced GMMMG guidance.
13	Adalimumab	N	Cytokine modulators	10.1.3	Group	Juvenile Arthritis					
14	Adalimumab	N	Cytokine modulators	10.1.3	Group	Uveitis [paediatric]					
15	Adalimumab	N	Cytokine modulators	10.1.3	Group	Uveitis [adult]					
16	Adalimumab	C	Cytokine modulators	10.1.3	Group	Ankylosing spondylitis	Monitored	NICE TA383 / GM Harmonised Pathway for biologics in AS and PsA.	http://guidance.nice.org.uk/TA383 http://gmmmg.nhs.uk/docs/guidance/GMMMG%20AS%20PsA%20pathway%20v4%20FINAL.pdf		
17	Adalimumab	C	Cytokine modulators	13.5.3	Group	Psoriasis (plaque)	Monitored	NICE TA146	http://guidance.nice.org.uk/TA146		
18	Adalimumab	C	Cytokine modulators	10.1.3	Group	Psoriatic Arthritis	Monitored	NICE TA199 / GM Harmonised Pathway for biologics in AS and PsA.	http://guidance.nice.org.uk/TA199 http://gmmmg.nhs.uk/docs/guidance/GMMMG%20AS%20PsA%20pathway%20v4%20FINAL.pdf		
19	Adalimumab	C	Cytokine modulators	13.5.3	Group	Psoriasis (plaque) - sequential use of biologic agents	Monitored	GMMMG	http://gmmmg.nhs.uk/docs/guidance/GMMMG-Biologics-pathway-for-psoriasis-v2-0.pdf	reference to psoriasis pathway updated	
20	Adalimumab	C	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis, after failure of conventional DMARDs	Monitored	NICE TA375 / GM Harmonised biologics pathway	http://www.nice.org.uk/guidance/ta375 http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-v4-1.pdf		
21	Adalimumab	C	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis, after failure of TNF inhibitor, if rituximab contra-indicated, or as monotherapy if rituximab and methotrexate contra-indicated	Monitored	NICE TA195 / GM Harmonised biologics pathway	http://guidance.nice.org.uk/TA195 http://gmmmg.nhs.uk/docs/guidance/GMMMG%20RA%20Pathway%202022%20april_2015.pdf		
22	Adalimumab	C	Cytokine modulators	1.5.3	Group	Crohn's Disease, gastroenterology	Monitored	NICE TA187	http://guidance.nice.org.uk/TA187		
23	Adalimumab	C	Cytokine modulators	1.5.3	Group	Ulcerative colitis, gastroenterology	Monitored	NICE TA329	http://www.nice.org.uk/guidance/ta329		
24	Adalimumab	C	Cytokine modulators	10.1.3	Group	All other adult indications	Individual funding				
25	Adalimumab	N	Cytokine modulators	10.1.3	Group	Paediatric indications (where adult TA available)		TA 455 or as per adult TA's (TA103, TA375, TA143, TA199)		Funding for paediatric indications not being treated at an NHSE-commissioned Specialist Centre may also fall to CCGs	
26	Adalimumab	N	Cytokine modulators	10.1.3	Group	Behçet's Syndrome				Added to match NHSE s/sheet	
27	Adefovir	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3	Group	Hepatitis B					
28	Afamelanotide	C	Skin Conditions	13.1	Individual	Erythropoietic protoporphyria (EPP)	Individual funding			Approved in the EU and UK for prophylactic treatment in adult patients with EPP.	

29	Afatinib	N	Protein kinase inhibitors	8.1.5	Individual					
30	Aflibercept	N	Cancer exclusion	8.1		Cancer				Added to match NHSE s/sheet
31	Aflibercept	C	Subfoveal choroidal neovascularisation	11.8.2	Individual	Neovascular (wet) age-related macular degeneration (AMD)	Monitored	NICE TA294	http://guidance.nice.org.uk/TA294	
32	Aflibercept	C	Subfoveal choroidal neovascularisation	11.8.2	Individual	Visual impairment caused by macular oedema secondary to central retinal vein occlusion	Monitored	NICE TA305	http://www.nice.org.uk/guidance/TA305	
33	Aflibercept	C	Subfoveal choroidal neovascularisation	11.8.2	Individual	Visual impairment caused by macular oedema secondary to branch retinal vein occlusion	Monitored	NICE TA 409	https://www.nice.org.uk/guidance/ta409	New entry for positive NICE TA for this indication.
34	Aflibercept	C	Subfoveal choroidal neovascularisation	11.8.2	Individual	Diabetic macular oedema	Monitored	NICE TA346	http://www.nice.org.uk/guidance/ta346	
35	Aflibercept	C	Subfoveal choroidal neovascularisation	11.8.3	Individual	Myopic choroidal neovascularisation	Monitored	NICE TA486	https://www.nice.org.uk/guidance/ta486	New entry for positive NICE TA for this indication.
36	Agalsidase alfa	N	Lysosomal Storage Disorder drugs	9.8.1	Group	Fabry's disease				
37	Agalsidase beta	N	Lysosomal Storage Disorder drugs	9.8.1	Group	Fabry's disease				
38	Aganirsen	N*	Subfoveal choroidal neovascularisation	11.8.2	Individual	Corneal neovascularisation associated with keratoplasty rejection				2018 NHSE commissions keratoplasty [PSS No.12]
39	Alafenamide	N	AIDS/HIV antiretrovirals		Group	HIV				Tenofovir alafenamide is a pro-drug of tenofovir with the aim of improving renal and bone safety - should really be with tenofovir which is where NHSE lists it.
40	Albutrepenonacog alfa	N	Blood-related products except Fibrin Sealants	2.11	Group	Haemophilia B				
41	Albutropin	N	Growth Hormone & growth hormone Receptor Antagonist	6.5.1	Individual	Growth hormone deficiency adult onset				An albumin/somatropin fusion protein that acts as a growth hormone receptor agonist. Commissioner changed to NHSE as per V11 s/sheet 2018.
42	Aldesleukin	N	Immunomodulating drugs	8.2.4	Individual	cancer				
43	Alemtuzumab	N	Drugs affecting the immune response	8.2.3	Individual	Multiple Sclerosis				
44	Alemtuzumab	N	Drugs affecting the immune response	8.2.3	Individual	Pre-transplant immunosuppression				
45	Alemtuzumab	N	Drugs affecting the immune response	8.2.3	Individual	CLL				
46	Alemtuzumab	N	Drugs affecting the immune response	8.2.3	Individual	Behçet's Syndrome				Added to match NHSE s/sheet
47	Alglucosidase alfa (Lumizyme® Myozyme®)	N	Lysosomal Storage Disorder drugs	9.8.1	Group	Pompe disease - late onset (pts 8yrs & over)				
48	Alipogene Tiparovec	N	Drugs used in Metabolic disorders	9.8	Individual	Hyperlipoproteinaemia				
49	Alirocumab	C	Lipid regulating drugs	2.12	Individual	Hypercholesterolaemia	Monitored	NICE TA393	https://www.nice.org.uk/guidance/ta393	

50	Alisporivir	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	none	Group	Hepatitis C				
51	Alitretinoin	C	Skin Conditions	13.5.1	Individual	Severe chronic hand eczema in adults	Monitored	NICE TA177	http://guidance.nice.org.uk/TA177	
52	Alpha-1 Antitrypsin	N	Drugs used in Metabolic disorders	3	Individual	Alpha-1 anti-trypsin deficiency: Emphysema				Intravenous and inhaled
53	Alpha-1 Antitrypsin	N	Drugs used in Metabolic disorders	6.1	Individual	Alpha-1 anti-trypsin deficiency: Type 1 diabetes mellitus in children.				Intravenous
54	Alpha-Mannosidase recombinant human	N	Lysosomal Storage Disorder drugs	none	Group					
55	Alteplase	C				Acute ischaemic stroke	Monitored	NICE TA264	http://guidance.nice.org.uk/TA264	Removed from national list. However, a locally agreed tariff for hyper acute stroke units has agreed that this can be re-charged to commissioners.
56	Ambrisentan	N	Vasodilator antihypertensive drugs/Pulmonary Arterial Hypertension	2.5.1	Individual	Pulmonary hypertension				
57	Amifampridine phosphate	N	Neuromuscular Disorders	10.2.1	Individual	Lambert-Eaton Myasthenic Syndrome or Congenital Myasthenia Gravis				
58	Amikacin Inhalation	C	Antibacterial Drugs	5.1.4	Individual	Ventilator Assisted Pneumonia	Individual Funding			
59	Amikacin Inhalation	N	Antibacterial Drugs	5.1.4	Individual	Cystic fibrosis	Individual Funding			Added to match NHSE s/sheet
60	Amikacin liposomal	N	Antibacterial Drugs		Individual	Management of cystic fibrosis				
61	Amphotericin liposomal	N	Antifungals	5.2.3	Individual	Licensed indications and/or Consultant Microbiologist approval only				
62	Anakinra	C	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis, rheumatology [adults]	Exceptional case	NICE CG79	http://www.nice.org.uk/guidance/CG79	Not recommended by NICE for RA; former TA72 now incorporated into updated CG79
63	Anakinra	N	Cytokine modulators	10.1.3	Group	Juvenile Arthritis				
64	Anakinra	N	Cytokine modulators	10.1.3	Group	Paediatric indications				
65	Anakinra	N	Cytokine modulators	10.1.3	Group	Specialist Autoinflammatory disease				
66	Anakinra	N	Cytokine modulators	10.1.3	Group	Cryopyrin Associated Periodic Syndrome				
67	Anidulafungin	N	Antifungals	5.2.4	Individual	Invasive candidiasis				
68	Antihaemophilic Factor/von Willebrand Factor Complex	N	Blood-related products except Fibrin Sealants	2.11	Group	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from PbR)				
69	Antilymphocyte globulin	N	Drugs used in hypoplastic, haemolytic and renal anaemias	9.1.3	Group	Licensed indications				

70	Anti-pseudomonas aeruginosa IgY	N	Antibacterial Drugs	5.1.7	Individual	Pseudomonas Aeruginosa Vaccine	Individual Funding			Pseudomonas aeruginosa in ventilated ICU patients - to prevent infections in Cystic Fibrosis patients
71	Antithrombin III	N	Blood related products	2.11	Group	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from PbR)				
72	Antithymocyte Immunoglobulin	N	Drugs used in hypoplastic, haemolytic and renal anaemias	8.2.2	Group	Licensed indications				
73	Apremilast	C	Cytokine modulators	none	Group	Psoriasis	Monitored	NICE TA419	https://www.nice.org.uk/guidance/ta419	NICE TA now positive
74	Apremilast	C	Cytokine modulators	none	Group	Psoriatic arthritis	Exceptional case; will change to monitored if final NICE guidance becomes positive. Due February 17.	NICE TA372	https://www.nice.org.uk/guidance/ta372	Being re-evaluated by NICE; Final Appraisal Determination document positive (subject to criteria)
75	Apremilast	N	Cytokine modulators	none	Group	Paediatric indications				
76	Aragam	N	Intravenous/subcutaneous human normal immunoglobulins	14.5.1	Group	Antibody deficiency syndromes, Immunology, Neurology				
77	Asfotase alfa	N	Lysosomal Storage Disorder drugs	9.8.1	Group	Hypophosphatasia				
78	Asunaprevir	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3	Group	Hepatitis C				
79	Asunaprevir + Daclatasvir	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3	Group	Hepatitis C				NHSE s/sheet shows this combination.
80	Asunaprevir + Beclabuvir + Daclatasvir	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3	Group	Hepatitis C				This combination not on official lists but is being trialled.
81	Atacicept	N	Drugs affecting the immune response	8.2.2	Individual	Systemic lupus erythematosus (SLE)				
82	Ataluren	N	Neuromuscular Disorders	3	Individual	Cystic fibrosis				
83	Ataluren	N	Neuromuscular Disorders	10.2	Individual	Duchenne Muscular Dystrophy				
84	Atazanavir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
85	Atazanavir and Cobicistat	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				Added to match NHSE s/sheet
86	Avacincaptad pegol	C	Subfoveal choroidal neovascularisation		Individual	Age-related macular degeneration (AMD); geographic atrophy (advanced dry-type AMD).	Individual funding			2019
87	Avatrombopag	C	Platelet Disorder Drugs	9.1.4	Individual	Chronic immune Thrombocytopenic purpura (ITP), thrombocytopenia	Individual funding			
88	Avoralstat	N	Allergic Emergencies	3.4.3	Individual	First line prevention of hereditary angioedema				

89	Axitinib	N	Protein kinase inhibitors	8.1.5	Individual					
90	Azacitidine	N	Myelodysplastic Syndrome	8.1.3	Individual					
91	Aztreonam Lysine [nebulised]	N	Antibacterial Drugs	5.1.2.3	Individual	Management of cystic fibrosis				
92	Baricitinib	C	Immunomodulating drugs	10.1.3	Individual	Rheumatoid arthritis - selective JAK1 and JAK2 inhibitor	Monitored	NICE TA466	https://www.nice.org.uk/guidance/ta466 http://gmimg.nhs.uk/docs/guidance/GMMMG-RA-pathway-v4-1.pdf	NICE TA referenced
93	Basiliximab	N	Corticosteroids and other immunosuppressants	8.2.2	Individual	Prophylaxis of acute organ rejection - Adolescents and children				
94	Beclabuvir	N	Viral Hepatitis (B&C) & Respiratory Syncytial Virus	5.3.3	Group	Hepatitis C				Annex C has inserted this as a separate entry but only combination products in NDO.
95	Bedaquiline	N	Antituberculosis drugs	5.1.9	Individual	Extensively drug resistant TB				Two rows to match NHSE s/sheet
96	Bedaquiline	N	Antituberculosis drugs	5.1.9	Individual	Multi drug resistant				Two rows to match NHSE s/sheet
97	Begelomab	N	Malignant disease and immunosuppression	8	Individual	Graft versus host disease (GvHD)				Marketing application withdrawn pending receipt of further data. Included only for completeness and match to national list.
98	Belatacept	N	Drugs affecting the immune response	8.2.2	Individual	Prevention of organ rejection following renal transplant				
99	Belimumab	N	Drugs affecting the immune response		Individual	Systemic lupus erythematosus (SLE)				
100	Benralizumab	N	Allergen Immunotherapy		Group	Asthma - uncontrolled on high-dose inhaled corticosteroid + LABA - in adults and adolescents				Monoclonal antibody binding to the interleukin-5 receptor that depletes eosinophils. 2017
101	Benralizumab	C	Allergen Immunotherapy		Group	COPD	Individual funding			Monoclonal antibody binding to the interleukin-5 receptor that depletes eosinophils. 2019
102	Beractant	N	Pulmonary surfactants	3.5.2	Individual	Respiratory Distress Syndrome				
103	Betaine	N	Drugs used in Metabolic disorders	9.8.1	Individual	Homocystinuria, tetrahydrofolate reductase deficiency, cobalamin cofactor metabolism.				
104	Bevacizumab	C	Antineoplastic drugs	11.8.2	Individual	AMD	Individual funding	GMMMG	http://gmimg.nhs.uk/docs/guidance/GMMMG%20recommendation%20Bevacizumab%20wAMD%20Nov%2015.pdf	
105	Bevacizumab	N	Antineoplastic drugs	8.1.5	Individual	Cancer				
106	Bevacizumab	N	Antineoplastic drugs	8.1.5	Individual	Neurofibromatosis				
107	Bimagrumab	N	Cytokine modulators		Group	Myopathy sporadic inclusion body myositis (sIBM) - first-line				
108	Biotin	N	?	9.6	Individual	Multiple Sclerosis				
109	Blisibimod	N	Cytokine modulators	10.1.3	Group	Systemic lupus erythematosus				
110	Boceprevir	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3	Group	Hepatitis C				

111	Bortezomib	N	Antineoplastic drugs	8.1.5	Individual	Cancer				
112	Bortezomib	N	Antineoplastic drugs	8.1.5	Individual	Organ rejection post kidney transplant				Added to match NHSE s/sheet
113	Bosentan	N	Vasodilator antihypertensive drugs/Pulmonary Arterial Hypertension	2.5.1	Individual	Pulmonary hypertension				
114	Bosentan	N	Vasodilator antihypertensive drugs/Pulmonary Arterial Hypertension	2.5.1	Individual	Digital ulcers				
115	Bosutinib	N	Protein kinase inhibitors	8.1.5	Individual	Chronic myelogenous leukaemia (CML)				
116	Botulinum toxin	C	Torsion Dystonias and other involuntary movements	4.9.3	Group	Prevention of headaches in chronic migraine.	Monitored	Migraine only: NICE TA260	http://guidance.nice.org.uk/TA260	
117	Botulinum toxin	C	Torsion Dystonias and other involuntary movements	4.9.3	Group	Hyperhidrosis	Monitored	GM	When used in line with local GM policy: <i>GM Hyperhidrosis Policy v1.0 Final</i> , available from CCG websites	
118	Botulinum toxin	C	Torsion Dystonias and other involuntary movements	4.9.3	Group	All other uses including torsion dystonias, involuntary movements,	Monitored / Individual Funding	GM	http://gmimg.nhs.uk/docs/guidance/Botulinum-toxin-policy-1-0-080218.pdf	Please check local GM policy.
119	Botulinum toxin	N	Torsion Dystonias and other involuntary movements	4.9.3	Group	Focal spasticity in children				
120	Botulinum toxin	N	Torsion Dystonias and other involuntary movements	4.9.3	Group	Intravesical use in spinal cord injury				
121	Brincidofovir	N	Cytomegalovirus infection	5.3.3.2	Individual	In allogeneic haematopoietic stem cell transplant				
122	Brodalumab	C	Immunomodulating drugs	13.5.3	Individual	Psoriasis [IL-17 receptor blocker]	Individual Funding			NICE TA expected 30/5/18. If positive, category changes to monitored when used in line with the TA. NHSE states on V11 that it will be responsible for paediatric indications should a positive NICE TA become available for adult indications.
123	Brodalumab	C	Immunomodulating drugs	10.1.3	Individual	Psoriatic arthritis [IL-17 receptor blocker]	Individual Funding			policy will be required. SPS suggests 2018
124	Brolucizumab	C	Subfoveal choroidal neovascularisation	11.8.2	Individual	Neovascular (wet) age-related macular degeneration (AMD)	Individual Funding			NOT in SPS
125	C1 Esterase inhibitor	N	Allergic Emergencies	3.4.3	Individual	Acute attack and prophylactic treatment of hereditary angioedema				
126	Canakinumab <i>Ilaris</i>	C	Immunomodulating drugs	8.2.4	Individual	Treating gouty arthritis attacks and reducing the frequency of subsequent attacks	Exceptional case	NICE TA281	http://guidance.nice.org.uk/TA281	NICE TAG terminated - unable to recommend use
127	Canakinumab <i>Ilaris</i>	N	Immunomodulating drugs	8.2.4	Individual	Autoimmune disorders [e.g. CAPS, MWS, NOMID, CINCA, FCAS, FCU]				
128	Canakinumab <i>Ilaris</i>	N	Immunomodulating drugs	8.2.4	Individual	Juvenile arthritis				

129	Carglumic acid	N	Drugs used in Metabolic disorders	9.8.1	Individual	Urea cycle disorders, Hyperammonaemia				
130	Carnitine	N	Drugs used in Metabolic disorders	9.8.1	Individual	Primary and secondary carnitine deficiency, haematology / amino acid supplement, renal medicine				
131	Caspofungin	N	Antifungals	5.2.4	Individual					
132	Catridecacog	N	Blood-related products except Fibrin Sealants	2.11	Group	Congenital factor XIII A-subunit deficiency				
133	Ceralifimod	N			Group	Multiple sclerosis (MS)				not in SPS list; drug development cancelled. Included here to match national list.
134	Cerliponase alfa	N	Central Nervous System		Individual	Neuronal ceroid lipofuscinosis - late infantile type 2 (CLN2), a form of Batten disease				
135	Certolizumab Pegol	N	Cytokine modulators	10.1.3	Group	Any paediatric use				
136	Certolizumab Pegol	C	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis, rheumatology,	Monitored	NICE TA375 / GM Harmonised biologics pathway	http://www.nice.org.uk/guidance/ta375 http://gmmmg.nhs.uk/docs/guidance/GMMMG%20RA%20Pathway%2022%20april_2015.pdf	
137	Certolizumab Pegol	C	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis: for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor	Monitored	NICE TA415	https://www.nice.org.uk/guidance/ta415	
138	Certolizumab Pegol	C	Cytokine modulators	10.1.3	Group	Ankylosing spondylitis	Monitored	NICE TA383 / GM Harmonised Pathway for biologics in AS and PsA.	http://guidance.nice.org.uk/TA383 http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-Final-v4.pdf	
139	Certolizumab Pegol	C	Cytokine modulators	10.1.3	Group	Psoriatic arthritis	Monitored	GM Harmonised Pathway for biologics in AS and PsA.	https://www.nice.org.uk/guidance/ta445 http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-Final-v4.pdf	NICE TA referenced
140	Certolizumab Pegol	C	Cytokine modulators	10.1.3	Group	Crohn's Disease, gastroenterology	Individual funding			
141	Cetuximab	N	Antineoplastic drugs	8.1.5	Individual	Cancer				
142	Chenodeoxycholic acid	N	Drugs used in Metabolic disorders		Group	Cerebrotendinous xanthomatosis Primary Biliary Cirrhosis				A lipid storage disorder. Expected Q4 2016.
143	Cholic acid	N	Drugs used in Metabolic disorders	none	Individual	Inborn errors in primary bile acid synthesis				
144	Cidofovir	N	Antiviral drugs	5.3.2.2	Individual	Cytomegalovirus infections				
145	Ciprofloxacin inhalation	N	Antibacterial Drugs	5.1.12	Individual	Bronchiectasis				Only when given by inhalation / nebulisation.
146	Ciprofloxacin liposomal	N	Antibacterial Drugs	5.1.12	Individual	Bronchiectasis				Only when given by inhalation / nebulisation.
147	Cladribine	N	Immunomodulating drugs	8.1.3	Individual	Multiple Sclerosis				

148	Cladribine	N	Immunomodulating drugs	8.1.3	Individual	Pulmonary Langerhans histiocytosis				
149	Cobicistat	N	AIDS/HIV antiretrovirals		Group	HIV in combination with other anti-retroviral drugs				
150	Cobitolimod	C	Drugs affecting the immune response		Individual	Ulcerative colitis (UC) refractory, 3rd line	Individual funding			2019
151	Co-careldopa internal tube intestinal gel	N	Neurodegenerative conditions	4.9.1	Individual	Advanced parkinsons (via PEG)				
152	Colistimethate sodium	N	Antibacterial Drugs	5.1.7	Individual	Management of cystic fibrosis				
153	Collagenase (outpatient use only)	C	Enzymes	10.1.3	Individual	Dupytren's contracture	Monitored	NICE TA 459	https://www.nice.org.uk/guidance/ta459	Use in line with NICE / GM policy.
154	Collagenase (outpatient use only)	C	Enzymes	10.1.3	Individual	Frozen Shoulder / Peyronie's Disease / any other use	Individual funding			Any other use that's not Dupytren's in line with GM policy
155	Conestat alfa (Recombinant C1 Esterase inhibitor)	N	Allergic Emergencies	3.4.3	Individual	Acute attack of hereditary angiodema				
156	Crizotinib	N	Protein kinase inhibitors	8.1.5	Individual	Cancer				
157	Darvadstrocel (CX601, Alofisel)	C	Drugs affecting the immune response	1.5.3	Individual	Perianal fistulas in Crohn's Disease	Individual funding			Expected 2018. Policy will be required. Allogeneic, expanded, adipose-derived stem cells
158	Cysteamine bitartrate (also known and shown as mercaptamine)	N	Drugs used in Metabolic disorders	9.8.1	Individual	Nephropathic cystinosis				
159	Cysteamine hydrochloride	N*	Drugs used in Metabolic disorders	11.1	Individual	Cystinosis [Corneal cystine crystals]				SPS says will be NHS England funded. Dropcys eye drops (0.1% solution)
160	Dabrafenib	N	Protein kinase inhibitors	8.1.5	Individual	Cancer				
161	Daclatasvir	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3	Individual	Hepatitis C				
162	Daclizumab	N	Corticosteroids and other immunosuppressants	8.2	Group	Organ transplant				No information regarding this use in SPS so removed.
163	Daclizumab	N	Corticosteroids and other immunosuppressants	8.2	Group	Multiple Sclerosis				Drug withdrawn. To be removed at next refresh.
164	Damoctocog alfa pegol	N*	Fibrinolytics	2.11	Individual	Haemophilia A prophylaxis and treatment				Not on NHSE V11 s/sheet yet was on V10 and no note. Treatment of haemophilia is commissioned by NHSE.
165	Darunavir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
166	Darunavir + cobicistat	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				included to match NHSE list
167	Dasabuvir	N	Viral Hepatitis (B&C) & Respiratory Syncytial Virus	5.3.3	Group	Hepatitis C				
168	Dasatinib	N	Protein kinase inhibitors	8.1.5	Individual	Cancer				
169	Decitabine	N	Myelodysplastic Syndrome	8.1.3	Individual	Cancer				
170	Deferasirox	C	Drugs used in hypoplastic, haemolytic, and renal anaemias - Iron overload	9.1.3	Group	Iron chelation in thalassaemia and sickle cell: myelodysplastic syndrome	Monitored			CCGs commission use in myelodysplastic syndrome

171	Deferasirox	N	Drugs used in hypoplastic, haemolytic, and renal anaemias - Iron overload	9.1.3	Group	Iron chelation in thalassaemia and sickle cell				
172	Deferiprone	C	Drugs used in hypoplastic, haemolytic, and renal anaemias - Iron overload	9.1.3	Group	Iron chelation in thalassaemia and sickle cell: myelodysplastic syndrome	Monitored			CCGs commission use in myelodysplastic syndrome
173	Deferiprone	N	Drugs used in hypoplastic, haemolytic, and renal anaemias - Iron overload	9.1.3	Group	Iron chelation in thalassaemia and sickle cell				
174	Defibrotide	N	Blood-related products except Fibrin Sealants	none	Group	Hepatic veno-occlusive disease				
175	Delamanid	N	Antituberculosis drugs	5.1.9	Individual	Extensively drug resistant TB				Two rows to match NHSE s/sheet
176	Delamanid	N	Antituberculosis drugs	5.1.9	Individual	Multi drug resistant TB				Two rows to match NHSE s/sheet
177	Desferrioxamine	C	Drugs used in hypoplastic, haemolytic, and renal anaemias - Iron overload	9.1.3	Group	Iron chelation in thalassaemia and sickle cell: myelodysplastic syndrome	Monitored			CCGs commission use in myelodysplastic syndrome
178	Desferrioxamine	N	Drugs used in hypoplastic, haemolytic, and renal anaemias - Iron overload	9.1.4	Group	Iron chelation in thalassaemia and sickle cell				
179	Dexamethasone intravitreal implant	C	Macular Oedema		Individual	Macular oedema secondary to retinal vein occlusion	Monitored	NICE TA229	http://guidance.nice.org.uk/T A229	
180	Dexamethasone intravitreal implant	C	Macular Oedema		Individual	Diabetic macular oedema	Monitored	NICE TA349	https://www.nice.org.uk/guidance/ta349	
181	Dexamethasone intravitreal implant	C	Macular Oedema		Individual	Inflammation of the posterior segment of the eye presenting as non-infectious uveitis	monitored	NICE TA460	https://www.nice.org.uk/guidance/ta460	
182	Dexrazoxane	N	Immunomodulating drugs	8.1	Group	Anthracycline cardiotoxicity				
183	Dexrazoxane	N	Immunomodulating drugs	8.1	Group	Anthracycline extravasation				
184	Dibotermin alfa	N	Bone morphogenetic protein	none	Individual	Complex spinal injury				
185	Dibotermin alfa	C	Bone morphogenetic protein	none	Individual	Orthopaedics / other than complex spinal surgery	Individual funding			
186	Didanosine	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
187	Digoxin immune fab	C	Poisoning	16.3.2 (BNF 70)	Individual	Digoxin toxicity	Monitored			
188	Dimethyl fumarate	C	Immunomodulating drugs	13.5	Individual	Dermatology: plaque psoriasis, moderate to severe	Monitored	NICE TA475	https://www.nice.org.uk/guidance/ta475	
189	Dimethyl fumarate	N	Immunomodulating drugs	8.2.2	Individual	Multiple Sclerosis, neurology				
190	Dolutegravir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				

191	Doravirine	N	AIDS/HIV antiretrovirals	5.3.2	Group	HIV in combination with other anti-retroviral drugs				
192	Dornase alfa	N	Mucolytics	3.7	Individual	Management of cystic fibrosis				
193	Dornase alfa	N	Mucolytics	3.7	Individual	Primary ciliary dyskinesia				Added to match NHSE s/sheet
194	Drisapersen	N	Neuromuscular Disorders	10.2	Individual	Duchenne Muscular Dystrophy				
195	Dupilumab	C	Drugs affecting the immune response		Group	Atopic dermatitis; moderate-to-severe	Individual funding			GMMMG recommendation in production; please consult when available pending NICE TA due 01/08/18
196	Dupilumab	N	Drugs affecting the immune response		Group	Asthma; persistent, add-on therapy	Individual funding			anti-interleukin-4 receptor (IL-4R) and anti-interleukin-13 receptor (IL-13R) human monoclonal antibody. 2019
197	Ecallantide	N	Allergic emergencies	none	Individual	Hereditary angioedema - acute treatment				Drug withdrawn but still appears in NHSE list! IFR required
198	Ecuzumab	N	Paroxysmal nocturnal haemoglobinuria	9.1.3	Individual	Organ rejection post transplant C3 glomerulopathy (post transplant)				Added to match NHSE s/sheet
199	Ecuzumab	N	Paroxysmal nocturnal haemoglobinuria	9.1.3	Individual	Atypical hemolytic uremic syndrome				
200	Ecuzumab	N	Paroxysmal nocturnal haemoglobinuria	9.1.3	Individual	Paroxysmal nocturnal haemoglobinuria				
201	Edratide	N	Drugs affecting the immune response	8.2	Group	systemic lupus erythematosus (SLE)				Not in SPS
202	Efavirenz	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
203	Efralotocog alfa	N	Platelet Disorder Drugs		Individual	Haemophilia A				NHSE V11 also states efmorotocog alfa / Factor VIII FC fusion protein with this drug
204	Eftrenonacog alfa	N	Platelet Disorder Drugs	2.11	Individual	Haemophilia B				
205	Elbasvir	N	Viral Hepatitis (B&C) & Respiratory Syncytial Virus	5.3.3	Group	Hepatitis C				
206	Eliglustat	N	Lysosomal Storage Disorder drugs	9.8.1	Group	Gaucher's Disease				
207	Elosulfase alfa	N	Lysosomal Storage Disorder drugs	none	Individual	Mucopolysaccharidosis IV type A				
208	Eltrombopag	C	Platelet Disorder Drugs	9.1.4	Individual	Chronic Immune Thrombocytopenic purpura (ITP)	Monitored	NICE TA293	http://guidance.nice.org.uk/TA293	While eltrombopag and romiplostim are the responsibility of CCGs regardless of the cause of the thrombocytopenia in adults, paediatrics are NHSE responsibility.
209	Eltrombopag	C	Platelet Disorder Drugs	9.1.4	Individual	Severe aplastic anaemia refractory to immunosuppressive therapy	Exceptional case	NICE TA382	http://www.nice.org.uk/guidance/ta382	Terminated NICE appraisal. New row to account for additional licensed indication.
210	Elvitegravir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				

211	Elvitegravir with cobicistat, emtricitabine and tenofovir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				Not in Annex C but kept in to accord with NHSE s/sheet. No longer listed in NHSE V11 so will be removed for next version.
212	Elvucitabine	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
213	Emricasan	N			Group	Hepatitis C infection liver fibrosis after liver transplant				
214	Emtricitabine	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				NHSE V11 adds the combination with tenofovir alafenamide to this entry; will be added as a separate row on next version of this list.
215	Emtricitabine with rilpivirine and tenofovir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
216	Enfuvirtide	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
217	Entecavir	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3	Group	Hepatitis B				HIV indication removed [not licensed nor on NHSE list]
218	Enzalutamide	N	Hormone antagonists [not official PbR category]	8.3.4.2		Cancer				Added to match NHSE s/sheet
219	Epoprostenol	N	Vasodilator antihypertensive drugs/Pulmonary Arterial Hypertension	2.8.1	Individual	Pulmonary Arterial Hypertension				Use in vascular disease is commissioned by NHSE within specialist centres. All other indications are CCG commissioned [ref. NHSE]
220	Epratuzumab	N	Cytokine modulators	10.1.3	Group	CD22 antigen inhibitor for Systemic lupus erythematosus (SLE)				
221	Eprodiasate	N	Drugs used in hypoplastic, haemolytic and renal anaemias	9.1	Group	Amyloidosis				While NHSE commissions diagnostic service for patients with amyloidosis from Highly Specialist Amyloidosis centres, CCGs commission most treatments [PSS 46]. However NHSE states that it is responsible commissioner for this drug, although it is not routinely commissioned and therefore requires IFRs submitting to NHSE
222	Eptotermin alfa	N	Bone morphogenetic protein	none	Group	Complex spinal injury				
223	Eptotermin alfa	C	Bone morphogenetic protein	none	Group	Orthopaedics / other than complex spinal surgery	Individual Funding			
224	Erlotinib	N	Protein kinase inhibitors	8.1.5	Individual	Cancer				
225	Etanercept	N	Cytokine modulators	10.1.3	Group	Paediatric indications (where adult TA available)		TA 455 or as per adult TA's (TA103, TA375, TA143, TA199)		

226	Etanercept	N	Cytokine modulators	10.1.3	Group	Juvenile arthritis			http://gmmmg.nhs.uk/docs/subgroups/sbgrp-hcdsg/Child-to-adult-services-statement-amended-post-meeting.pdf	For children transitioning to adult services and becoming a CCG commissioning responsibility, category is monitored when in line with the referenced GMMMG guidance.
227	Etanercept	C	Cytokine modulators	10.1.3	Group	Ankylosing spondylitis	Monitored	NICE TA383 / GM Harmonised Pathway for biologics in AS and PsA.	http://guidance.nice.org.uk/TA383 http://gmmmg.nhs.uk/docs/guidance/GMMMG%20AS%20PsA%20pathway%20v4%20FINAL.pdf	
228	Etanercept	C	Cytokine modulators	10.1.3	Group	Psoriasis (plaque)	Monitored	NICE TA103	http://guidance.nice.org.uk/TA103	
229	Etanercept	C	Cytokine modulators	10.1.3	Group	Psoriasis (plaque) - sequential use of biologic agents	Monitored	GMMMG	http://gmmmg.nhs.uk/docs/guidance/GMMMG-Biologics-pathway-for-psoriasis-v2-0.pdf	reference to psoriasis pathway updated
230	Etanercept	C	Cytokine modulators	10.1.3	Group	Psoriatic Arthritis	Monitored	NICE TA199 / GM Harmonised Pathway for biologics in AS and PsA.	http://guidance.nice.org.uk/TA199 http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-Final-v4.pdf	reference to AS/ PsA pathway updated
231	Etanercept	C	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis, after failure of conventional DMARDs	Monitored	NICE TA375 / GM Harmonised biologics pathway	http://www.nice.org.uk/guidance/ta375 http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-v4-1.pdf	reference to GMMMG RA pathway updated
232	Etanercept	C	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis, after failure of TNF inhibitor, if rituximab contra-indicated, or as monotherapy if rituximab and methotrexate contra-indicated	Monitored	NICE TA195 / GM Harmonised biologics pathway	http://guidance.nice.org.uk/TA195 http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-v4-1.pdf	reference to GMMMG RA pathway updated
233	Etanercept	C	Cytokine modulators	10.1.3	Group	All other adult indications	Individual funding			
234	Eteplirsen	N	Neuromuscular disorders		Group	Duchenne muscular dystrophy; amenable to exon 51 skipping				
235	Etravirine	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
236	Etrolizumab	C	Drugs affecting the immune response	1.5.3	Individual	Ulcerative colitis (UC) naive to TNF inhibitors and refractory to or intolerant of prior immunosuppressant and/or corticosteroid treatment	Individual Funding			2019 NHSE states on V11 that it will be responsible for paediatric indications should a positive NICE TA become available for adult indications.
237	Etrolizumab	C	Drugs affecting the immune response	1.5.3	Individual	Crohn's disease moderate-to-severe	Individual Funding			2020
238	Everolimus <i>Afinitor</i>	N	Protein kinase inhibitors	8.1.5	Individual	Cancer				
239	Everolimus <i>Certican</i>	N	Protein kinase inhibitors			Preventing organ rejection in heart and liver transplantation				Added to match NHSE s/sheet

240	Everolimus <i>Votubia</i>	N	Protein kinase inhibitors	8.1.5	Individual	Renal angiomyolipoma associated with tubular sclerosis				
241	Everolimus <i>Votubia</i>	N	Protein kinase inhibitors	8.1.5	Individual	Subependymal giant cell astrocytoma (SEGA) and renal angiomyolipoma associated with tubular sclerosis				two indications will be separated on next version
242	Evolocumab	C	Lipid regulating drugs	2.12	Individual	Hypercholesterolaemia	Monitored		https://www.nice.org.uk/guidance/ta394	
243	Evolocumab	N	Lipid regulating drugs	2.12	Individual	Homozygous familial hypercholesterolaemia				
244	Ex-vivo expanded autologous human corneal epithelial cells containing stem cells 1 <i>Holoclar</i>	N		?	Individual	Orphan market exclusivity for "Treatment of corneal lesions, with associated corneal (limbal) stem cell deficiency, due to ocular burns"				Treatment of adult patients with moderate to severe limbal stem cell deficiency (defined by the presence of superficial corneal neovascularisation in at least two corneal quadrants, with central corneal involvement, and severely impaired visual acuity), unilateral or bilateral, due to physical or chemical ocular burns.
245	Factor IX	N	Blood-related products	2.11	Group	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from PbR)				
246	Factor VII	N	Blood-related products	2.11	Group	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from PbR)				
247	Factor VIIa (Eptacog alfa)	N	Blood-related products	2.11	Group	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from PbR)				
248	Factor VIII	N	Blood-related products	2.11	Group	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from PbR)				
249	Factor VIII Fc fusion protein	N*	Blood-related products	2.11	Group	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from PbR)				Not on NHSE V11 s/sheet yet was on V10 and no note. Treatment of haemophilia is commissioned by NHSE.
250	Factor VIII inhibitor bypassing factor	N	Blood-related products	2.11	Group	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from PbR)				
251	Factor XIII	N	Blood-related products	2.11	Group	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from PbR)				
252	Fampridine	N	Neuromuscular Disorders	10.2.1	Individual	Multiple Sclerosis				

253	Fasimumab	C	Cytokine Modulators	4.7	Group	Osteoarthritis	Individual Funding			2019
254	Fibrin sealants (Tisseel)	C	Blood related products			Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from PbR)	Monitored			Removed from national and this list for 2017/19
255	Fibrinogen	N	Blood related products	2.11	Group	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from PbR)				
256	Fibroblast growth factor 1 gene therapy	N	Somatostatin Analogues	None	Group					
257	Filgotinib	C	Drugs affecting the immune response	1.5.3	Individual	Crohn's disease	Individual Funding			2019 NHSE states on V11 that it will be responsible for paediatric indications should a positive NICE TA become available for adult indications.
258	Filgotinib	C	Drugs affecting the immune response	10.1.3	Individual	Rheumatoid arthritis (RA); moderate-to-severe	Individual Funding			2019
259	Filgrastim	N	Drugs used in neutropenia	9.1.6	Group	Neutropenia				New separate row for use in neutropenia as per NHSE s/sheet
260	Filgrastim	N	Drugs used in neutropenia	9.1.6	Group	Barth Syndrome				
261	Filibuvir	N	Viral Hepatitis (B&C) & Respiratory Syncytial Virus	5.3.3	Group	Hepatitis C				NHSE states that it is responsible commissioner for this drug. Drug development discontinued in 2013! Not in SPS.
262	Fingolimod	N	Immunomodulating drugs	8.2.4	Individual	Multiple Sclerosis				
263	Fitusiran	N	Blood-related products	2.11	Individual	Haemophilia				not in SPS
264	Flebogamma	N	Intravenous/subcutaneous human normal immunoglobulins	14.5.1	Group	Antibody deficiency syndromes, Immunology, Neurology				
265	Flebogammadif	N	Intravenous/subcutaneous human normal immunoglobulins	14.5.1	Group	Antibody deficiency syndromes, Immunology, Neurology				
266	Fluocinolone acetonide	C	Macular Oedema	11.4.1	Individual	Treatment of diabetic macular oedema	Monitored	NICE TA301	http://guidance.nice.org.uk/TA301	
267	Fomepizole	C	Poisoning	none	Individual	Emergency treatment of poisoning >Other poisons >Ethylene glycol and methanol >Fomepizole	Monitored		In line with recommendations from National Poisons Information Service http://www.npis.org/	
268	Forigerimod acetate Lupuzor	N	Drugs affecting the immune response		Individual	Systemic lupus erythematosus (SLE)				
269	Fosamprenavir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
270	Foscarnet	N	Cytomegalovirus infection	5.3.2.2	Individual	Cytomegalovirus infection				
271	Fostatinib disodium	C	Protein kinase inhibitors	9.1	Individual	Idiopathic thrombocytopenic purpura (ITP)	Individual Funding			Likely indication is CCG-commissioned (SPS says NHSE). Spleen tyrosine kinase (Syk) inhibitor. 2018

272	Fostemsavir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV infection				2019
273	Galcanezumab	C	Cytokine modulators	4.7	Group	Cluster headache; chronic and episodic; prevention	Individual Funding			2018
274	Galcanezumab	C	Cytokine modulators	4.7.4	Group	prevention of episodic migraine	Individual Funding			2019
275	Galsulfase	N	Lysosomal Storage Disorder drugs	9.8.1	Group	Mucopolysaccharidosis VI [6 = Matoteaux-Lamy syndrome]				
276	Gammagard S/D	N	Intravenous/subcutaneous human normal immunoglobulins	14.5.1	Group	Antibody deficiency syndromes, Immunology, Neurology				
277	Gammanorm	N	Intravenous/subcutaneous human normal immunoglobulins	14.5.1	Group	Antibody deficiency syndromes, Immunology, Neurology				
278	Gammaplex	N	Intravenous/subcutaneous human normal immunoglobulins	14.5.1	Group	Antibody deficiency syndromes, Immunology, Neurology				
279	Gamunex	N	Intravenous/subcutaneous human normal immunoglobulins	14.5.1	Group	Antibody deficiency syndromes, Immunology, Neurology				
280	Ganciclovir	N	Cytomegalovirus infection	5.3.2.2	Individual	Cytomegalovirus infection				
281	Ganetespi	N	Immunomodulating drugs	8.2.4	Individual	Non-small cell lung cancer (NSCLC) and acute myeloid leukaemia (AML)				
282	Gantenerumab	C	Drugs for dementia	4.11	Individual	Alzheimer's disease	Individual Funding			2019
283	Gefitinib	N	Protein kinase inhibitors	8.1.5	Individual	Cancer				
284	Gevokizumab	N	Immunomodulating drugs	11.4.2 / 6.1.2.3	Individual	Antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). Uveitis				All development discontinued for uveitis. Also trialled in type 2 diabetes mellitus but unlikely to progress in this indication.
285	Glatiramer acetate	N	Immunomodulating drugs	8.2.4	Individual	Multiple Sclerosis, neurology				
286	Glecaprevir	N	Viral Hepatitis (B&C) & Respiratory Syncytial Virus		Group	Hepatitis C				
287	Glucarpidase	N	Poisoning	None	Individual	For the urgent treatment of methotrexate-induced renal dysfunction				NHSE has commissioning policy B15/P/a
288	Glycerol phenylbutyrate	N	Drugs used in Metabolic disorders	9.8.1	Individual	Urea cycle disorders - hyperammonaemia in adults and children ≥2 months of age				
289	GlycoPEGylated Factor IX	N	Blood-related products except Fibrin Sealants		Group	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from PbR)				
290	Golimumab	N	Cytokine modulators		Group	Any paediatric use		As per adult TAs	http://gmmmg.nhs.uk/docs/subgroups/sbgrp-hcdsg/Child-to-adult-services-statement-amended-post-meeting.pdf	For children transitioning to adult services and becoming a CCG commissioning responsibility, category is monitored when in line with the referenced GMMMG guidance.

291	Golimumab	C	Cytokine modulators		Group	Ankylosing spondylitis	Monitored	NICE TA497	http://guidance.nice.org.uk/TA497 http://gmimg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-Final-v4.pdf	reference to AS/ PsA pathway updated
292	Golimumab	C	Cytokine modulators		Group	Psoriatic arthritis	Monitored	NICE TA220 / GM Harmonised Pathway for biologics in AS and PsA.	http://guidance.nice.org.uk/TA220 http://gmimg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-Final-v4.pdf	reference to AS/ PsA pathway updated
293	Golimumab	C	Cytokine modulators		Group	Rheumatoid arthritis (Methotrexate naïve)	Monitored	NICE TA375	http://www.nice.org.uk/guidance/ta375 http://gmimg.nhs.uk/docs/guidance/GMMMG-RA-pathway-v4-1.pdf	reference to RA pathway updated
294	Golimumab	C	Cytokine modulators		Group	Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs)	Monitored	NICE TA375	http://www.nice.org.uk/guidance/ta375 http://gmimg.nhs.uk/docs/guidance/GMMMG-RA-pathway-v4-1.pdf	reference to RA pathway updated
295	Granulocyte-macrophage colony-stimulating factor (<i>Leukine</i> - Import)	N	Drugs used in neutropenia			Antibody-positive pulmonary alveolar proteinosis				Not in Annex B1 but in NHSE s/sheet
296	Grazoprevir	N	Viral Hepatitis (B&C) & Respiratory Syncytial Virus	5.3.3	Group	Hepatitis C				Will be a combination product with elbasvir.
297	Guselkumab	C	Drugs affecting the Immune response	13.5.3	Individual	psoriasis	Individual Funding			Targets IL-23. Possibly available in 2017. Not on NICE's agenda so may require local evaluation.
298	Halofuginone	N*	Neuromuscular Disorders		Individual	Duchenne muscular dystrophy				
299	HIV vaccine	N		14	Group	HIV				
300	Hizentra	N	Intravenous/subcutaneous human normal immunoglobulins	14.5.1	Group	Antibody deficiency syndromes, Immunology, Neurology				
301	Human Arginate	N	Drugs used in Metabolic disorders	9.8.2	Individual	Hepatic porphyria				
302	Human Heterologous Liver Cells	N	Drugs used in Metabolic disorders	9.8.1	Individual	Urea cycle disorders in children				
303	Human Parathyroid hormone-related protein analogue	C	Drugs affecting bone metabolism	6.6.1	Individual	postmenopausal osteoporosis	Individual Funding			This is abaloparatide (row 5)
304	Human Parathyroid hormone-related protein analogue	N	Drugs affecting bone metabolism	6.6.1	Individual	Male and juvenile osteoporosis				This is abaloparatide (row 5)
305	Hyqvia	N	Intravenous/subcutaneous human normal immunoglobulins	14.5.1	Group					
306	Ibalizumab	N	AIDS/HIV antiretrovirals	5.3.1	Individual					Not in SPS
307	Icatibant	N	Allergic Emergencies	3.4.3	Individual	Hereditary angioedema - acute and prophylactic treatment				Prophylactic treatment added to accord with V11
308	Idebenone	N	Neuromuscular Disorders	10.2	Individual	Duchenne muscular dystrophy				

309	Idebenone	N*	Neuromuscular Disorders	4	Individual	Friedreich's ataxia				Separate row now: Not in NHSE V11 s/sheet but expected to commission as NHSE commissions for other neurodegenerative disorders.
310	Idebenone <i>Raxone</i>	N*	Neuromuscular Disorders	11.8	Individual	Visual impairment in adolescent and adult patients with Leber's Hereditary Optic Neuropathy (LHON).				Not in NHSE V11 s/sheet but expected to commission as NHSE commissions other rare mitochondrial diseases. Licensed.
311	Idursulfase	N	Lysosomal Storage Disorder Drugs	9.8.1	Group	Mucopolysaccharidosis II [2]				
312	Iloprost (nebulised)	N	Vasodilator antihypertensive drugs/Pulmonary Arterial Hypertension	2.5.1	Individual	Pulmonary hypertension				Use in vascular disease is commissioned by NHSE within specialist centres. All other indications are CCG commissioned [ref. NHSE]
313	Imatinib	N	Protein kinase inhibitors	8.1.5	Individual	Cancer				
314	Imatinib	N	Protein kinase inhibitors	8.1.5	Group	Graft versus host disease				
315	Imiglucerase	N	Lysosomal Storage Disorder Drugs	9.8.1	Group	Non-neurological manifestations of type I or type III Gaucher's disease.				
316	Indinavir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
317	Infliximab	N	Cytokine modulators	10.1.3	Group	Paediatric indications (where adult TA available)				
318	Infliximab	N	Cytokine modulators	10.1.3	Group	Juvenile arthritis			http://gmmmg.nhs.uk/docs/subgroups/sbgrp-hcdsg/Child-to-adult-services-statement-amended-post-meeting.pdf	For children transitioning to adult services and becoming a CCG commissioning responsibility, category is monitored when in line with the referenced GMMMG guidance.
319	Infliximab	N	Cytokine modulators	10.1.3	Group	Connective tissue disease - interstitial lung disease				
320	Infliximab	N	Cytokine modulators	10.1.3	Group	Crohn's Disease in children		NICE TA187		
321	Infliximab	N	Cytokine modulators	10.1.3	Group	Graft versus host disease				
322	Infliximab	N	Cytokine modulators	10.1.3	Group	Renal				
323	Infliximab	N	Cytokine modulators	10.1.3	Group	Sarcoidosis				
324	Infliximab	N	Cytokine modulators	10.1.3	Group	Uveitis [adult and child]				
325	Infliximab	N	Cytokine modulators	10.1.3	Group	Hidradenitis suppurativa				
326	Infliximab	N	Cytokine modulators	10.1.3	Group	Behçet's Syndrome				Added to match NHSE s/sheet
327	Infliximab	C	Cytokine modulators	10.1.3	Group	Ankylosing spondylitis	Monitored	NICE TA383 / GM Harmonised Pathway for biologics in AS and PsA.	http://guidance.nice.org.uk/TA383 http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-Final-v4.pdf	reference to GMMMG AS/PsA pathway updated
328	Infliximab	C	Cytokine modulators	10.1.3	Group	Psoriasis (plaque)	Monitored	NICE TA134	http://guidance.nice.org.uk/TA134 http://gmmmg.nhs.uk/docs/guidance/GMMMG-Biologics-pathway-for-psoriasis-v2-0.pdf	reference to GMMMG psoriasis pathway updated

329	Infliximab	C	Cytokine modulators	10.1.3	Group	Psoriasis (plaque) - sequential use of biologic agents	Monitored	GMMMG	http://gmmmg.nhs.uk/docs/guidance/GMMMG-Biologics-pathway-for-psoriasis-v2-0.pdf	reference to GMMMG psoriasis pathway updated
330	Infliximab	C	Cytokine modulators	10.1.3	Group	Psoriatic Arthritis	Monitored	NICE TA199 / GM Harmonised Pathway for biologics in AS and PsA.	http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-Final-v4.pdf	reference to GMMMG As/ PsA pathway updated
331	Infliximab	C	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis, after failure of conventional DMARDs	Monitored	NICE TA375 / GM Harmonised biologics pathway	http://www.nice.org.uk/guidance/ta375 http://gmmmg.nhs.uk/docs/guidance/GMMMG%20AS%20PsA%20pathway%20v4%20FINAL.pdf	New row inserted for this indication.
332	Infliximab	C	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis, after failure of TNF inhibitor, if rituximab contra-indicated	Monitored	NICE TA195	http://guidance.nice.org.uk/TA195 http://gmmmg.nhs.uk/docs/guidance/GMMMG%20RA%20Pathway%202022%20april_2015.pdf	
333	Infliximab	C	Cytokine modulators	10.1.3	Group	Crohn's Disease, gastroenterology	Monitored	NICE TA187	http://guidance.nice.org.uk/TA187	
334	Infliximab	C	Cytokine modulators	10.1.3	Group	Moderately to severely active ulcerative colitis after the failure of conventional therapy	Monitored	NICE TA329	http://www.nice.org.uk/guidance/ta329	New row inserted for this indication for clarity.
335	Infliximab	C	Cytokine modulators	10.1.3	Group	Acute exacerbations of ulcerative colitis	Monitored	NICE TA163	http://guidance.nice.org.uk/TA163	
336	Infliximab	C	Cytokine modulators	10.1.3	Group	Sub-acute manifestations of ulcerative colitis	Monitored	NICE TA329	http://www.nice.org.uk/guidance/ta329	
337	Infliximab	C or N, seek guidance if necessary	Cytokine modulators	10.1.3	Group	All other indications	Individual funding			
338	Interferon alfa	N	Immunomodulating drugs	8.2.4	Individual	Hepatitis B+C				
339	Interferon beta	N	Immunomodulating drugs	8.2.4	Individual	Multiple sclerosis				
340	Intratect	N	Intravenous/subcutaneous human normal immunoglobulins	14.5.1	Group	Antibody deficiency syndromes, Immunology, Neurology				
341	Isavuconazole	N	Antifungals	5.2	Individual	Fungal infection				
342	Ivacaftor	N	Mucolytics	3.7	Individual	Management of cystic fibrosis				
343	Ixazomib	N	Drugs used in hypoplastic, haemolytic and renal anaemias	8.1.5	Group	Multiple myeloma (MM) / amyloidosis				
344	Ixekizumab	C	Cytokine modulators	13.5.3	Group	Psoriasis	Monitored	NICE TA442	https://www.nice.org.uk/guidance/ta442 http://gmmmg.nhs.uk/docs/guidance/GMMMG-Biologics-pathway-for-psoriasis-v2-0.pdf	references to NICE and GMMMG psoriasis pathway updated

345	Ixekizumab	C	Cytokine modulators	13.5.3	Group	Psoriatic arthritis	Individual funding		Spelling error in drug name continues on latest national lists. May be marketed for this indication in 2018. Policy required.
346	Ixekizumab	C	Cytokine modulators	13.5.3	Group	Ankylosing Spondylitis	Individual funding		Spelling error in drug name continues on latest national lists. SPS suggests this indication not until 2019. Policy may be required.
347	Ketorolac with Phenylephrine	C	Retinal disorders/intraocular lens replacement surgery	11.8.2	Individual	Intraocular lens replacement surgery	Individual funding		Do we need a policy on this? Licensed as Omidria 10 mg/mL + 3 mg/mL concentrate for solution for intraocular irrigation.
348	Kiovig	N	Intravenous/subcutaneous human normal immunoglobulins	14.5.1	Group	Antibody deficiency syndromes, Immunology, Neurology			
349	Lamivudine	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.1	Group	Hepatitis B			
350	Lamivudine	N	AIDS/HIV antiretrovirals		Group	HIV in combination with other anti-retroviral drugs			
351	Lampalizumab	C	Subfoveal choroidal neovascularisation	11.8	Group	Geographic atrophy secondary to <u>dry</u> age-related macular degeneration	Individual funding		2019
352	Lanreotide	N	Somatostatin Analogues	8.3.4.3	Group	Cancer			
353	Lanreotide	N	Somatostatin Analogues	8.3.4.3	Group	Acromegaly			NHSE is the responsible commissioner when somatropin analogues are prescribed in Specialist Centres for indications falling outside NICE guidance.
354	Lanreotide	N	Somatostatin Analogues	8.3.4.3	Group	Congenital hyperinsulinism - children only			
355	Lanreotide	C or N, seek guidance if necessary	Somatostatin Analogues	8.3.4.3	Group	Congenital hyperinsulinism - adults	Individual funding		NHSE has indicated that the responsible commissioner for this use is the commissioner for the service caring for the patient.
356	Lanreotide	C	Somatostatin Analogues	8.3.4.3	Group	Other than NHSE commissioned indications	Licensed indications: monitored. Unlicensed indications: Individual funding		
357	Lapatinib	N	Protein kinase inhibitors	8.1.5	Individual	Cancer			
358	Laquinimod	N	Immunomodulating drugs	8.2.4	Individual	Multiple sclerosis			Back in Annex B1 so replaced back into this s/sheet. EMA: not recommended for approval.
359	Laronidase	N	Lysosomal Storage Disorder Drugs	9.8.1	Group	Non-neurological manifestations of Mucopolysaccharidosis I (1)			

360	Lebrikizumab	N	Allergen Immunotherapy		Group	Asthma - various possible indications	Individual Funding		IL-13 inhibitor. However, SPS says asthma programme discontinued after primary outcome not met in a Phase III clinical trial.
361	Ledipasvir* [and in combination with sofosbuvir]	N*	Viral Hepatitis (B&C) & Respiratory Syncytial Virus		Group	Hepatitis C			
362	Lenalidomide	N	Immunomodulating drugs	8.2.4	Individual	Cancer and POEMS syndrome			POEMS is new to NHSE V13. These 2 indications will be separated on the next version.
363	Lenograstim	N	Drugs used in neutropenia	9.1.6	Group	Neutropenia			
364	Lenograstim	N	Drugs used in neutropenia	9.1.6	Group	Barth Syndrome			
365	Letermovir	N	Cytomegalovirus infection		Group	Cytomegalovirus infection			2018
366	Levodopa + Carbidopa	N*	Neurodegenerative Conditions	4.9.1	Group	Parkinson's Disease			Unique delivery mode (i.e. intestinal gel). Not a new drug. Arguably duplicates row 151 (both descriptions present in National List).
367	Levofloxacin (inhaled)	N	Antibacterial Drugs	5.1.12	Individual	Management of cystic fibrosis			
368	Lipegfilgrastim	N	Drugs used in neutropenia	9.1.6	Group	Neutropenia			
369	Lixivaptan	N	Vasopressin V2 receptor antagonist	6.5.2	Individual	Hyponatraemia and other endocrine uses			
370	Lomitapide	N	Lipid regulating Drugs	2.12	Individual	Homozygous familial hypercholesterolemia			
371	Lonafarnib	N	Protein kinase inhibitors		Group	Hepatitis D infection (with ritonavir) and / or cancer			2018
372	Lopinavir with Ritonavir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs			
373	Lumacaftor with Ivacaftor	N	Mucolytics		Individual	Not in BNF (Ivacaftor shown as BNF 3.7 on list) Cystic fibrosis			
374	Lusutrombopag <i>Mulpleta</i>	N*?	Platelet Disorder Drugs		Individual	Thrombocytopenia			In adults with chronic liver disease prior to undergoing elective invasive procedures to reduce the need for platelet transfusions
375	Macimorelin	N	Growth Hormone & growth hormone Receptor Antagonist	6.5	Individual	Growth failure			
376	Macitentan	N	Vasodilator antihypertensive drugs/Pulmonary Arterial Hypertension	2.5.1	Individual				
377	Mannitol (inhaled)	N	Mucolytics	3.7	Individual	Management of cystic fibrosis.			
378	Maraviroc	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs			
379	Masitinib	N	Protein kinase inhibitors	8.1.5	Individual	Pancreatic cancer / GIST			

380	Mavrilimumab	C	Drugs affecting the Immune response	10.1.3	Individual	Rheumatoid arthritis	Individual funding		2020 NHSE states on V11 that it will be responsible for paediatric indications should a positive NICE TA become available for adult indications.
381	Mecasermin	N	Growth Hormone & growth hormone Receptor Antagonist	6.7.4	Individual	Growth failure			
382	Mepolizumab	N	Allergen Immunotherapy	3.4.2	Individual	Asthma			
383	Mepolizumab	N*	Allergen Immunotherapy	3.4.3	Individual	Churg Strauss syndrome			
384	Mepolizumab	C	Allergen Immunotherapy	3.4.4	Individual	COPD	Individual Funding		SPS says COPD use is CCG commissioned
385	Mercaptamine (cysteamine)	N	Drugs used in Metabolic disorders	9.8.1	Individual	Nephropathic cystinosis			duplicates row 158 but both descriptions present in National list.
386	Metreleptin	N*	Other endocrine drugs	6.7	Individual	Lipodystrophy			SPS says use is NHSE commissioned
387	Metreleptin	N	Other endocrine drugs	6.7	Individual	Dyslipidaemia			as per entry on V11
388	Micafungin	N	Antifungals	5.2.4	Individual	Invasive candidiasis (risk of liver tumours)			
389	Migalastat	N	Lysosomal Storage Disorder Drugs	9.8.1	Group	Fabry's disease			
390	Miglustat	N	Lysosomal Storage Disorder Drugs	9.8.1	Group	Mild to moderate type I Gaucher's disease, Niemann-Pick type C disease			
391	Momelotinib	N	Protein kinase inhibitors		Group	Pancreatic cancer / myelofibrosis			2018
392	Motavizumab	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	none	Group	RSV prophylaxis			
393	Natalizumab	N	Immunomodulating drugs	8.2.4	Individual	Multiple sclerosis			
394	Nelfinavir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs			
395	Nevirapine	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs			
396	Nilotinib	N	Protein kinase inhibitors	8.1.5	Individual	Cancer			
397	Nintedanib Vargatef	N	Immunomodulating drugs	8.1.5	Individual	Ovarian cancer			
398	Nintedanib Ofev	N	Immunomodulating drugs	8.1.5	Individual	Idiopathic pulmonary fibrosis			
399	Nintedanib Vargatef	N	Immunomodulating drugs	8.1.5	Individual	Non small cell lung cancer			
400	Nitazoxanide	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	none	Group	Hepatitis C			
401	Nitisinone	N	Drugs used in Metabolic disorders	9.8.1	Individual	Hereditary tyrosinemia type 1			
402	Nitisinone	N	Drugs used in Metabolic disorders	9.8.1	Individual	Alkaptonuria			
403	Nitric Oxide	N	Vasodilator antihypertensive drugs/Pulmonary Arterial Hypertension	none	Individual	Pulmonary arterial hypertension			

404	Nonacog alpha	N	Blood-related products except Fibrin Sealants	none	Group	Haemophilia B				
405	Nonacog beta pegol	N	Blood-related products except Fibrin Sealants	none	Group	Haemophilia B				
406	Normal Immunoglobulin	N	Intravenous/subcutaneous human normal immunoglobulins	14.5.1	Group	Antibody deficiency syndromes, Immunology, Neurology				
407	Obeticholic acid <i>Ocaliva</i>	N	Drugs used in Metabolic disorders		Individual	Primary biliary cirrhosis / Non-alcoholic steatohepatitis (NASH)				Q4 2016 2018
408	Ocrelizumab	N	Immunomodulating drugs	8.2.4	Individual	Multiple sclerosis				
409	Ocriplasmin	C	Retinal disorders	11.8.2	Individual	Focal vitreomacular adhesion (VMA)	Monitored	NICE TA297	http://guidance.nice.org.uk/TA297	
410	Octagam	N	Intravenous/subcutaneous human normal immunoglobulins	14.5.1	Group	Antibody deficiency syndromes, Immunology, Neurology				
411	Octocog Alfa	N	Platelet Disorder Drugs	2.11	Group	Haemophilia A				
412	Octreolin	N	Growth Hormone & growth hormone Receptor Antagonist	6.5	Individual	Acromegaly				
413	Octreotide	N	Somatostatin Analogues	8.3.4.3	Group	Cancer				
414	Octreotide	N	Somatostatin Analogues	8.3.4.3	Group	Acromegaly				NHSE is the responsible commissioner when somatropin analogues are prescribed in Specialist Centres for indications falling outside NICE guidance.
415	Octreotide	N	Somatostatin Analogues	8.3.4.3	Group	Congenital hyperinsulinism [children]				
416	Octreotide	C or N, seek guidance if necessary	Somatostatin Analogues	8.3.4.3	Group	Congenital hyperinsulinism [adults]	Individual funding			NHSE has indicated that the responsible commissioner for this use is the commissioner for the service caring for the patient.
417	Octreotide	C	Somatostatin Analogues	8.3.4.3	Group	Vomiting in palliative care, Entero-cutaneous fistula High output stoma Refractory diarrhoea	Licensed indications: monitored. Unlicensed indications: Individual funding except the indications listed adjacent for which the category is monitored	http://gmmmg.nhs.uk/docs/subgroups/sbgrp-hcdsg/Octreotide-gastro-recommendation.pdf		CCG commissioned for non-cancer use
418	Odanacatib	C	Drugs affecting bone metabolism	6.6.2	Individual	Osteoporosis [post menopausal]	Individual funding			SPS says development discontinued
419	Odanacatib	N*	Drugs affecting bone metabolism	6.6.3	Individual	Osteoporosis [men]	Individual funding			SPS says development discontinued; not in V11
420	Ofatumumab	N	Immunomodulating drugs	8.2.3	Individual	Cancer				

421	Ofatumumab	N	Immunomodulating drugs	8.2.3	Individual	Multiple sclerosis, pemphigus vulgaris, chronic lymphocytic leukaemia (CLL)	Individual funding		
422	Olesoxime	N	Neuromuscular Disorders	10.2	Individual	Cholesterol oxime mitochondrial pore modulator for spinal muscular atrophy.			
423	Omalizumab	N	Allergen Immunotherapy	3.4.2	Individual	IgE mediated severe asthma all persons 6years+			
424	Omalizumab	C	Allergen Immunotherapy	3.4.2	Individual	Chronic spontaneous urticaria	Monitored	NICE TA339	http://www.nice.org.uk/guidance/ta339
425	Ombitasvir with Paritaprevir with Ritonavir with Dasabuvir +/- ribavirin	N	Viral Hepatitis (B&C) & Respiratory Syncytial Virus	5.3.3	Group	Hepatitis C			
426	Osilodrostat	N	Other Endocrine drugs	6.7.3	Group	Cushing's disease			inhibitor of aldosterone synthase 2018
427	Ozanimod	N	Multiple sclerosis (MS)	8.2	Group	relapsing-remitting			2019
428	Ozanimod	C	IBD	1.5.3	Group	Ulcerative colitis (UC); moderate-to-severe active	Individual funding		2020
429	Pacritinib	N	Protein kinase inhibitors	8.1.5	Individual	Myelofibrosis			
430	Palivizumab	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.5	Group	RSV prophylaxis			
431	Para - Aminosalicilic acid	N	Antituberculosis drugs	5.1.9	Individual	Tuberculosis			
432	Parathyroid hormone	N	Drugs affecting bone metabolism	6.6.1	Individual	Specialist endocrinology conditions			Additional row added for consistency with NHSE spreadsheet
433	Parathyroid hormone	C	Drugs affecting bone metabolism	6.6.1	Group	Osteoporosis in women	Individual funding		
434	Parenteral Nutrition (after 14 days or where the patient is receiving TPN prior to admission)	C	Parenteral Nutrition	9.3	Group	Nutrition: Type I intestinal failure	Monitored		NHSE commissions TPN for intestinal failure types II and III but CCGs will commission TPN for Type I i.e. where the primary medical issue isn't one of sub-optimal bowel function. Further information is provided at the foot of the spreadsheet.
435	Parenteral Nutrition (after 14 days or where the patient is receiving TPN prior to admission)	N	Parenteral Nutrition	10.3	Group	Nutrition: Types II and III intestinal failure			NHSE commissions TPN for intestinal failure types II and III but CCGs will commission TPN for Type I i.e. where the primary medical issue isn't one of sub-optimal bowel function. Further information is provided at the foot of the spreadsheet.
436	Paritaprevir	N	Viral Hepatitis (B&C) & Respiratory Syncytial Virus	5.3.3	Group	Hepatitis C			
437	Pasireotide	N	Somatostatin Analogues	6.3.4.3	Group	Acromegaly			Two rows to match NHSE s/sheet
438	Pasireotide	N	Somatostatin Analogues	6.3.4.3	Group	Cushing's disease			Two rows to match NHSE s/sheet

439	Pazopanib	N	Protein kinase inhibitors	8.1.5	Individual	Cancer				
440	Pegaptanib	C	Subfoveal choroidal neovascularisation	11.8.2	Group	Wet age related macular degeneration, ophthalmology	Exceptional case	NICE TA155	http://guidance.nice.org.uk/TA155	
441	Pegfilgrastim	N	Drugs used in neutropenia	9.1.6	Individual	Neutropenia - where a single dose G-CSF is necessary				
442	Peginterferon alfa	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	8.2.4	Group	Hepatitis B and C				
443	Peginterferon Beta-1a	N	Immunomodulating drugs	8.2.4	Individual	Multiple sclerosis				
444	Peginterferon Lambda-1a	N	Immunomodulating drugs	8.2.4	Individual	Hepatitis C				
445	Pegloticase	C	Gout and cytotoxic-induced hyperuricaemia	10.1.4	Individual	Treatment of acute hyperuricaemia in patients with haematological malignancy	Exceptional case	NICE TA291	http://guidance.nice.org.uk/TA291	
446	Pegpleranib Fovista	C	Retinal disorders/intraocular lens replacement surgery	11.8.2	Individual	Wet-AMD	Individual funding			2018
447	Pegvisomant	N	Growth Hormone & growth hormone Receptor Antagonist	6.5.1	Individual	Acromegaly				
448	Pembrolizumab	N	Immunomodulating drugs	8.2.4		Treatment naïve melanoma (unresectable, metastatic)				N.B. This drug is not in Annex A (nor was it on last year's list) but is included here to match NHSE s/sheets V11 through 13
449	Pembrolizumab	N	Immunomodulating drugs	8.2.4		Melanoma (unresectable, metastatic)				"
450	Pirfenidone	N	Pulmonary Fibrosis	3.11	Individual	Idiopathic pulmonary fibrosis				
451	Plerixafor	N	Drugs affecting the immune response	9.1.7	Individual	Stem cell mobilisation				
452	Pomalidomide	N	Immunomodulating drugs	8.2.4	Individual	Cancer				
453	Pomalidomide	N	Immunomodulating drugs	8.2.4	Individual	Myelofibrosis and multiple myeloma				
454	Ponatinib	N	Protein kinase inhibitors	8.1.5	Individual	Chronic myelogenous leukaemia (CML), Acute lymphoblastic leukaemia (ALL)				
455	Ponesimod	N	Multiple sclerosis (MS)	10.2	Group	relapsing-remitting				2019
456	Poractant alfa	N	Pulmonary surfactants	3.5.2	Individual	Respiratory Distress Syndrome				
457	Porcine Factor	N*	Blood-related products except Fibrin Sealants	none	Individual	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from Pbr)				
458	Posaconazole	N	Antifungals	5.2.1	Individual	For all invasive fungal infections including those associated with transplants and aspergillosis				Note that treatment of Allergic bronchopulmonary aspergillosis (ABPA) is CCG-commisioned.
459	Pretomanid	N	Antibacterial Drugs	5.1.9	Group	Tuberculosis				Not in SPS

460	Privigen	N	Intravenous/subcutaneous human normal immunoglobulins	14.5.1	Group	Antibody deficiency syndromes, Immunology, Neurology			
461	Protein C	N	Blood related products	2.11	Group	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from PbR)			
462	Prothrombin Complex	N	Blood related products	2.11	Group	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from PbR)			
463	Raltegravir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs			
464	Ranibizumab	C	Subfoveal choroidal neovascularisation	11.8.2	Individual	Wet age related macular degeneration, diabetic macular oedema, branch and central retinal vein occlusion, choroidal neovascularisation secondary to pathological myopia	Monitored	NICE TA155 / 274 / 283 / 298	http://guidance.nice.org.uk/TA155 / 274 / 283 / 298
465	Rasburicase	N	Gout and cytotoxic-induced hyperuricaemia	10.1.4	Individual	Treatment of acute hyperuricaemia in patients with haematological malignancy			
466	Regorafenib	N	Protein kinase inhibitors	8.1.5	Individual	Cancer			
467	Reslizumab	N	Allergen Immunotherapy	3.4.2	Individual	Allergic, eosinophilic asthma			
468	Reveglucosidase alfa	N	Lysosomal Storage Disorder Drugs		Group	Pompe disease			2018
469	Ribavirin	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.5	Individual	Hepatitis C			
470	Rigosertib	N	Myelodysplastic Syndrome	8	Individual	Myelodysplastic Syndrome and pancreatic cancer			
471	Rilpivirine	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs			
472	Riluzole	C	Torsion Dystonias and other involuntary movements	4.9.3	Group	Amyotrophic lateral sclerosis in motor neurone disease, neurology	Monitored	NICE TA20	http://guidance.nice.org.uk/TA20
473	Riociguat	N	Vasodilator antihypertensive drugs/Pulmonary Arterial Hypertension	2.5.1	Individual	Pulmonary arterial hypertension			
474	Ritonavir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs			
475	Rituximab	N	Cytokine modulators	10.1.3	Group	ANCA-positive vasculitis			
476	Rituximab	N	Cytokine modulators	10.1.3	Group	Acquired haemophilia			
477	Rituximab	N	Cytokine modulators	10.1.3	Group	Steroid sensitive nephrotic syndrome			
478	Rituximab	N	Cytokine modulators	10.1.3	Group	Steroid resistant nephrotic syndrome			
479	Rituximab	N	Cytokine modulators	10.1.3	Group	Primary Sjogren's Syndrome (PSS)			

480	Rituximab	N	Cytokine modulators	10.1.3	Group	Chronic inflammatory demyelinating polyneuropathy				
481	Rituximab	N	Cytokine modulators	10.1.3	Group	Connective tissue disease - interstitial lung disease				
482	Rituximab	N	Cytokine modulators	10.1.3	Group	Graft versus host disease				
483	Rituximab	N	Cytokine modulators	10.1.3	Group	Myositis				
484	Rituximab	N	Cytokine modulators	10.1.3	Group	ABO-incompatible kidney transplants				
485	Rituximab	N	Cytokine modulators	10.1.3	Group	Nephritis				
486	Rituximab	N	Cytokine modulators	10.1.3	Group	Neuromyelitis Optica				
487	Rituximab	N	Cytokine modulators	10.1.3	Group	SLE				
488	Rituximab	N	Cytokine modulators	10.1.3	Group	Immunoglobulin G4 related disease				Added to match NHSE s/sheet
489	Rituximab	N	Cytokine modulators	10.1.3	Group	Neuromyelitis optica				Added to match NHSE s/sheet
490	Rituximab	N	Cytokine modulators	10.1.3	Group	Pemphigus Vulgaris				
491	Rituximab	N	Cytokine modulators	10.1.3	Group	Juvenile arthritis				
492	Rituximab	C	Cytokine modulators	10.1.3	Group	Refractory Primary Idiopathic Immune Cytopenias	Monitored		http://gmmmg.nhs.uk/docs/subgroups/sbgrp-hcdsq/GMMM-G-Rituximab-recommendation-final.pdf	Unlicensed. Includes Refractory Idiopathic Thrombocytopenia Purpura (ITP), Autoimmune Haemolytic Anaemia (AIHA) and Evans syndrome.
493	Rituximab	C	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis, after failure of TNF inhibitor, Rheumatology	Monitored	NICE TA195	http://guidance.nice.org.uk/TA195 http://gmmmg.nhs.uk/docs/guidance/GMMM-G-RA-pathway-v4-1.pdf	
494	Rituximab (IV)	N	Cytokine modulators	10.1.3	Group	Cancer				
495	Rituximab subcutaneous formulation	N	Cytokine modulators	10.1.3	Group	Cancer				
496	Rituximab	C or N, seek guidance if necessary	Cytokine modulators	10.1.3	Group	All other indications	Individual funding			
497	Romiplostim	C	Platelet Disorder Drugs	9.1.4	Individual	Chronic immune thrombocytopenic purpura (ITP)	Monitored	NICE TA221	http://www.nice.org.uk/guidance/TA221	While eltrombopag and romiplostim are the responsibility of CCGs regardless of the cause of the thrombocytopenia in adults, paediatrics are NHSE responsibility.
498	Ropeginterferon alfa-2b	N	Viral Hepatitis (B&C) & Respiratory Syncytial Virus		Group	Polycythemia vera; first-line				2017
499	Roxadustat	C	Drugs used in hypoplastic, haemolytic, and renal anaemias	9.1	Group	Anaemia in chronic kidney disease (non dialysis-dependent)	Individual funding			SPS says CCG commissioned. 2019
500	Roxadustat	N	Drugs used in hypoplastic, haemolytic, and renal anaemias	9.1	Group	Anaemia in chronic kidney disease (dialysis-induced)				SPS says CCG commissioned but use in dialysis-induced patients is confirmed by V11 to be NHSE. 2019
501	Ruxolitinib	N	Protein kinase inhibitors	8.1.5	Individual	Cancer				
502	Sandoglobulin	N	Intravenous/subcutaneous human normal immunoglobulins	14.5.1	Group	Antibody deficiency syndromes, Immunology, Neurology				

503	Sapropterin	N	Drugs used in Metabolic disorders	9.4.1	Individual	Hyperphenylalaninaemia (HPA) [children with phenylketonuria]				
504	Sapropterin	N	Drugs used in Metabolic disorders	9.4.1	Individual	Hyperphenylalaninaemia (HPA) [Maternal phenylketonuria]				
505	Saquinavir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
506	Sarilumab	C	Cytokine modulators	10.1.3	Group		Monitored	NICE TA485	https://www.nice.org.uk/guidance/ta485 http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-v4-1.pdf	references to NICE and GMMMG RA pathway updated
507	Sebelipase alfa	N	Lysosomal Storage Disorder Drugs	9.8.1	Group	Lysosomal acid lipase deficiency				
508	Secukinumab	N	Cytokine modulators	13.5.3	Group	Paediatric indications				
509	Secukinumab	C	Cytokine modulators	13.5.3	Group	Psoriasis	Monitored	NICE TA350	https://www.nice.org.uk/guidance/ta350 http://gmmmg.nhs.uk/docs/guidance/GMMMG-Biologics-pathway-for-psoriasis-v2-0.pdf	reference to GMMMG psoriasis pathway updated
510	Secukinumab	C	Cytokine modulators	10.1.3	Group	Psoriatic arthritis	Individual funding	NICE TA445	https://www.nice.org.uk/guidance/ta445 http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-Final-v4.pdf	references to NICE and GMMMG AS/ PsA pathway updated
511	Secukinumab	C	Cytokine modulators	10.1.3	Group	Active Ankylosing spondylitis	Monitored	NICE TA407	https://www.nice.org.uk/guidance/ta407 http://gmmmg.nhs.uk/docs/guidance/GMMMG-AS-PsA-pathway-Final-v4.pdf	references to GMMMG AS/ PsA pathway updated
512	Selexipag	N	Vasodilator antihypertensive drugs/Pulmonary Arterial Hypertension	2.5.1	Individual	Pulmonary arterial hypertension				
513	Serelaxin	C	Hypertension and heart failure		Individual	Acute decompensated heart failure	Individual funding			Drug still in development. Technology Appraisal currently suspended indefinitely by NICE. 2018
514	Setrobuvir	N	Viral Hepatitis (B&C) & Respiratory Syncytial Virus	5.3.3	Group	Hepatitis C				
515	Sialic acid	N	Drugs used in Metabolic disorders	9.8.1	Individual	Myopathy				Only PbR excluded when used for a metabolic disorder. Not in SPS.
516	Sildenafil (only when used for PAH)	N	Vasodilator antihypertensive drugs/Pulmonary Arterial Hypertension	2.5.1	Individual	Pulmonary arterial hypertension				
517	Siltuximab	N*	Cytokine modulators	8.2.4	Group	Castleman's Disease				
518	Simeprevir	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3	Group	Hepatitis C				
519	Simeprevir / peginterferon + ribavirin	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3	Group	Hepatitis C				Added to match NHSE s/sheet

520	Sirukumab	N*	Drugs affecting the immune response	10.1.3	Individual	Giant cell (temporal) arteritis				IL-6 inhibitor. 2019
521	Sirukumab	C	Drugs affecting the immune response	10.1.3	Individual	Rheumatoid arthritis	Individual Funding			IL-6 inhibitor. Possibly Q3 2017. Not on NICE's agenda. NHSE states on V11 that it will be responsible for paediatric indications should a positive NICE TA become available for adult indications.
522	Sodium benzoate	N*	Drugs used in Metabolic disorders		Individual					New addition to Annex A 2016 /17. Only PbRe when used in metabolic disorders. Not in proposed list for 2017/19 so removed N.B. This drug is not in Annex A but is included here to match NHSE s/sheet V11
523	Sodium oxybate	N	Hypnotics and anxiolytics	4.1.1	Individual	Narcolepsy - paediatric services only				
524	Sodium oxybate	C	Hypnotics and anxiolytics	4.1.1	Individual	Narcolepsy with cataplexy	Individual funding	GMMMG NTS	http://gmimg.nhs.uk/docs/nts/NTS%20Sodium%20Oxybate%20for%20narcolepsy.pdf	All requests to go to CCGs for detailed consideration at IFR Panels
525	Sodium phenylbutyrate	N	Drugs used in Metabolic disorders	9.8.1	Individual	Urea cycle disorders				
526	Sofosbuvir / daclatasvir + ribavirin	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3.2	Group	Hepatitis C				Entries now match NHSE s/ sheet
527	Sofosbuvir / ledipasvir +/- ribavirin	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3.2	Group	Hepatitis C				Entries now match NHSE s/ sheet
528	Sofosbuvir / peginterferon + ribavirin	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3.2	Group	Hepatitis C				Entries now match NHSE s/ sheet
529	Sofosbuvir / velpatasvir	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3.3	Group	Hepatitis C				Entries now match NHSE s/ sheet
530	Solanezumab	C	Drugs affecting the immune system	4.11	Individual	Alzheimer's disease	Individual Funding			2020
531	Somatropin	C	Growth Hormone & growth hormone Receptor Antagonist	6.5.1	Individual	Growth hormone deficiency children	Monitored	NICE TA188	http://www.nice.org.uk/guidance/TA188	
532	Somatropin	C	Growth Hormone & growth hormone Receptor Antagonist	6.5.1	Individual	Severe growth hormone deficiency in adults	Monitored	NICE TA64	http://www.nice.org.uk/guidance/TA64	
533	Sorafenib	N	Protein kinase inhibitors	8.1.5	Individual	Cancer				
534	Stavudine	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV in combination with other anti-retroviral drugs				
535	Subcuvia	N	Intravenous/subcutaneous human normal immunoglobulins	14.5.1	Group	Antibody deficiency syndromes, Immunology, Neurology				
536	Subgam	N	Intravenous/subcutaneous human normal immunoglobulins	14.5.1	Group	Antibody deficiency syndromes, Immunology, Neurology				
537	Sucoferric oxyhydroxide	N	Phosphate binding agents	9.5.2.2	Individual	Phosphate binding agent				End stage renal disease. V11 through 13 place this at the end within non-PbRe but it is on the National List as PbRe.

538	Sunitinib	N	Protein kinase inhibitors	8.1.5	Individual	Cancer				
539	Susoctocog alfa	N	Blood-related products except Fibrin Sealants	9.1.3	Group	Haemophilia A				
540	Tadalafil (only when used for PAH)	N	Vasodilator antihypertensive drugs/Pulmonary Arterial Hypertension	7.4.5	Individual	Pulmonary arterial hypertension				
541	Tafamidis <i>Vyndaqel</i>	N	Neurodegenerative Conditions	4.9.3	Individual	Amyloidosis; senile, systemic	Individual funding			Despite PSS 46 saying CCGs commission the majority of treatment services for patients with amyloidosis, NHSE V13 now lists this and so the commissioner has been changed to NHSE. The two indications rows 541 and 542 will be merged on the next version. 2022
542	Tafamidis <i>Vyndaqel</i>	N	Neurodegenerative Conditions		Individual	Cardiovascular disorders; transthyretin cardiomyopathy (TTR-CM)				NHSE commissioned on V13
543	Taliglucerase alfa	N	Lysosomal Storage Disorder Drugs		Group	Gaucher's disease				
544	Tanezumab	C	Cytokine modulators	4.7	Group	Osteoarthritis	Individual funding			2018
545	Taribavirin	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.5	Group	Hepatitis C				
546	Teduglutide	N	Cytokine modulators [GLP-2 analogue]	1	Group	Short bowel syndrome				
547	Telaprevir	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3	Group	Hepatitis C				
548	Telbivudine	N	Viral Hepatitis (B&C) & respiratory Syncytial Virus	5.3.3	Group	Hepatitis B				
549	Temsirolimus	N	Protein kinase inhibitors	8.1.5	Individual	Cancer				
550	Tenofovir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV (or Hepatitis with some drugs)				
551	Tenofovir with Emtricitabine	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV (or Hepatitis with some drugs)				
552	Tenofovir with Emtricitabine and Efavirenz	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV (or Hepatitis with some drugs)				
553	Tenofovir with emtricitabine and rilpivirine	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV (or Hepatitis with some drugs)				Further entries of combination products required to match NHSE s/ sheet but all products containing tenofovir are commissioned by NHSE
554	Teriflunomide	N	Immunomodulating drugs	8.2.4	Individual	multiple sclerosis				
555	Teriparatide	N	Drugs affecting bone metabolism	6.6.1	Individual	Osteoporosis in men and juveniles Osteogenesis imperfecta	Individual funding			
556	Teriparatide	C	Drugs affecting bone metabolism	6.6.1	Individual	Osteoporosis in women	Monitored	NICE TA161	http://guidance.nice.org.uk/TA161	

557	Tesamorelin	?	Growth Hormone & growth hormone Receptor Antagonist	13.1	Individual	HIV-associated lipodystrophy					SPS says filing withdrawn.
558	Tetrahydrobiopterin	N	Drugs used in Metabolic disorders	9.4.1	Individual	Hyperphenylalaninaemia (HPA)					
559	Tezacaftor	N	Mucolytics	3.7	Group	Cystic Fibrosis					national list says "for non-Cystic Fibrosis indications" yet only in SPS in combination with ivacaftor for CF. Category changed to NHSE as on V11.
560	Thalidomide	N	Immunomodulating drugs	8.2.4	Individual	Cancer					
561	Thrombin	N	Blood-related products except Fibrin Sealants	none	Group	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from PbR)					
562	Thrombomodulin, Recombinant Human	C	Fibrinolytics	2.10.2	Individual	Septic shock (Sepsis)	Individual Funding				2017
563	Tildrakizumab	C	Skin Conditions	13.5	Individual	Psoriasis	Individual Funding				IL-23 inhibitor, unlikely before 2020
564	Tipranavir	N	AIDS/HIV antiretrovirals	5.3.1	Individual	HIV (or Hepatitis with some drugs)					
565	Tobramycin	N	Antibacterial Drugs	5.1.4	Individual	Management of cystic fibrosis					
566	Tocilizumab IV	N	Cytokine modulators	10.1.3	Group	Paediatric indications (where adult TA available)				http://gmmmg.nhs.uk/docs/subgroups/sbgrp-hcdsg/Child-to-adult-services-statement-amended-post-meeting.pdf	For children transitioning to adult services and becoming a CCG commissioning responsibility, category is monitored when in line with the referenced GMMMG guidance.
567	Tocilizumab IV	N	Cytokine modulators	10.1.3	Group	Juvenile arthritis					
568	Tocilizumab IV	N	Cytokine modulators	10.1.3	Group	Giant Cell arteritis Takayasu arteritis					
569	Tocilizumab	C	Cytokine modulators	10.1.3	Group	Rheumatoid arthritis	Monitored		http://www.nice.org.uk/guidance/ta375		
570	Tofacitinib	N	Cytokine modulators		Group	Any paediatric use			NICE TA375 / GM Harmonised biologics pathway	http://gmmmg.nhs.uk/docs/guidance/GMMMG%20RA%20Pathway%2022%20april_2015.pdf	
571	Tofacitinib	C	Cytokine modulators	10.1.3	Group	Rheumatoid Arthritis	Monitored	https://www.nice.org.uk/guidance/ta480 http://gmmmg.nhs.uk/docs/guidance/GMMMG-RA-pathway-v4-1.pdf	https://www.nice.org.uk/guidance/ta480		reference to NICE and GMMMG RA pathway updated
572	Tofacitinib	C	Cytokine modulators	10.1.3, 1.5.4	Group	Psoriatic arthritis, ulcerative colitis	Individual funding				These are potential future indications
573	Tolvaptan Samsca	N	Vasopressin V2 receptor antagonist	6.5.2	Individual	Hyponatraemia in cancer					NHS England has stated that it is the responsible commissioner for this drug only when used in this indication.
574	Tolvaptan Samsca	C	Vasopressin V2 receptor antagonist	6.5.2	Individual	Hyponatraemia and other endocrine uses including SIADH	Individual funding				

575	Tolvaptan <i>Jinarc</i>	C	Vasopressin V2 receptor antagonist	6.5.2	Individual	Autosomal dominant polycystic kidney disease	Monitored	NICE TA358	http://www.nice.org.uk/guidance/ta358	New row inserted for this indication. CCG commissioned
576	Tralokinumab	N	Allergen Immunotherapy	3.4	Group	Asthma - severe				SPS says CCG-commissioned but on NHSE V11.
577	Trenonacog alpha	N	Blood-related products except Fibrin Sealants	2.11	Group	Haemophilia B				
578	Treprostinil diethanolamine	N	Vasodilator antihypertensive drugs/Pulmonary Arterial Hypertension	2.5.1	Individual	Pulmonary arterial hypertension				
579	Treprostinil sodium	N	Vasodilator antihypertensive drugs/Pulmonary Arterial Hypertension	2.5.1	Individual	Pulmonary arterial hypertension				
580	Trientine	N	Drugs used in Metabolic disorders		Individual	Wilson's Disease				Not a new drug. No licensed preparation available in UK; imported.
581	Turoctocog alfa	N	Blood related products	2.11	Group	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from Pbr)				intravenous formulation of recombinant factor VIII (octocog alfa, rFVIII)
582	Uridine triacetate	N*	Poisoning	9.8.1	Individual	Fluorouracil (5-FU) overexposure or toxicity				SPS suggests this use is NHSE-commissioned. Also used for hereditary orotic aciduria, an ultra-rare metabolic disorder. 2019
583	Ustekinumab	N	Drugs affecting the immune response	10.3 / 13.5	Individual	Paediatric indications (where adult TA available)				
584	Ustekinumab	C	Drugs affecting the immune response	13.5	Individual	Psoriasis (plaque)	Monitored	NICE TA180	http://guidance.nice.org.uk/TA180 GMMMG guidance for sequential use: http://gmmmg.nhs.uk/docs/guidance/GMMMG-Biologics-pathway-for-psoriasis-v2-0.pdf	reference to GMMMG pathway updated
585	Ustekinumab	C	Drugs affecting the immune response	10.3	Individual	Psoriatic arthritis	Monitored	NICE TA340	http://www.nice.org.uk/guidance/ta340 http://gmmmg.nhs.uk/docs/guidance/GMMMG%20AS%20PsA%20pathway%20v4%20FINAL.pdf	
586	Ustekinumab	C	Drugs affecting the immune response	1.5	Individual	Crohn's Disease	Monitored	NICE TA456	https://www.nice.org.uk/guidance/ta456 http://gmmmg.nhs.uk/docs/guidance/Biologics-pathway-for-Inflammatory-Bowel-Disease-in-Adults-v2-0.pdf	reference to NICE and GMMMG pathway updated
587	Ustekinumab	C	Drugs affecting the immune response	10.3	Individual	Any other use	Individual funding			

588	Vadadustat	C	Drugs used in hypoplastic, haemolytic, and renal anaemias	9.1	Group	Anaemia in chronic kidney disease (non dialysis-dependent)	Individual funding				Trials found for use in dialysis-dependent patients (NHSE) and non-dialysis-dependent patients (CCG)
589	Vadadustat	N	Drugs used in hypoplastic, haemolytic, and renal anaemias	9.1	Group	Anaemia in chronic kidney disease (dialysis-dependent)					Trials found for use in dialysis-dependent patients (NHSE) and non-dialysis-dependent patients (CCG)
590	Valganciclovir	N	Cytomegalovirus infection	5.3.2.2	Individual	CMV retinitis / Prophylaxis CMV +ve donor transplant					
591	Vancomycin	C?	Antibacterial Drugs	5.1.7	Individual						Unique delivery system only (thermosensitive mPEG-PLCPPA hydrogel?) Not in SPS
592	Vandetanib	N	Protein kinase inhibitors	8.1.5	Individual	Thyroid cancer					
593	Vapreotide	C	Growth Hormone & growth hormone Receptor Antagonist		Individual	Somatostatin analogue for Oesophageal varices	Individual Funding				
594	Vedolizumab	N	Drugs affecting the immune response	1.5.3	Individual	Paediatric indications (where adult TA available)					
595	Vedolizumab	C	Drugs affecting the immune response	1.5.3	Individual	Crohn's Disease	Monitored	NICE TA352		http://www.nice.org.uk/guidance/ta352	
596	Vedolizumab	C	Drugs affecting the immune response	1.5.3	Individual	Ulcerative colitis	Monitored	NICE TA342		http://www.nice.org.uk/guidance/ta342	
597	Velaglucerase alfa	N	Lysosomal Storage Disorder Drugs	9.8.1	Group	Gaucher's disease					
598	Velcalcetide	N	Drugs affecting bone metabolism	6.5	Individual	Hyperparathyroidism					
599	Vemurafenib	N	Protein kinase inhibitors	8.1.5	Individual	Melanoma					
600	Verteporfin	C	Subfoveal choroidal neovascularisation	11.8.2	Individual	Wet age related macular degeneration (with predominantly classic subfoveal chroidal neovascularisation (CNV)), ophthalmology	Monitored	NICE TA68		http://guidance.nice.org.uk/TA68	
601	Vigam	N	Intravenous/subcutaneous human normal immunoglobulins	14.5.1	Group	Antibody deficiency syndromes, Immunology, Neurology					
602	Vivaglobin	N	Intravenous/subcutaneous human normal immunoglobulins	14.5.1	Group	Antibody deficiency syndromes, Immunology, Neurology					
603	Von Willebrand factor, recombinant	N	Blood related products	2.11	Group	Licensed indications (Not all blood products are listed in the BNF, but they are all excluded from PbR)					
604	Voriconazole	N	Antifungals	5.2.1	Individual	For all invasive fungal infections including those associated with transplants					Note that treatment of Allergic bronchopulmonary aspergillosis (ABPA) is CCG-commisioned.
605	Voriconazole	N	Antifungals	5.2.1	Individual	Chronic pulmonary aspergillosis					

606	Winfuran (KP 1461)	N*	AIDS/HIV antiretrovirals		Individual					I think the National list is mixed up: winfuran would have been for treatment of severe uraemic pruritus in patients with end-stage kidney disease on dialysis but the EMA refused a MA on 19/12/13. KP-1461 is an anti HIV drug, the development status of which is currently unclear.
607	Ziconotide	N	Non-opioid analgesics	4.7.1	Individual	Severe, chronic pain				
608	Zidovudine	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV (or Hepatitis with some drugs)				
609	Zidovudine with Lamivudine	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV (or Hepatitis with some drugs)				
610	Zidovudine with Lamivudine and Abacavir	N	AIDS/HIV antiretrovirals	5.3.1	Group	HIV (or Hepatitis with some drugs)				

Other drugs not listed as Pbr exclusions but NHSE commissioned										
Note: NHSE has been clear that existing GP [=CCG] prescribing of these should NOT be repatriated to NHSE. This section is similar to NHSE's drug list Indications for NHS England drugs list v13 23/03/2018										
No.	Drug Name	Commissioner Category CDF = Cancer drugs fund - check with latest version of NHSE list	PBR Category	BNF category	Group	Indication	Prior Approval Category	Commissioning Policy Type	Commissioning Policy Link	Comments
	3,4 Diaminopyridine	N	Lambert Eaton Myasthenic Syndrome							
	Aflibercept	N	Cancer			Cancer				
	Albumin bound paclitaxel	N	Cancer			Treatment of breast cancer patients with documented taxane hypersensitivity				
	Atezolizumab	CDF	Cancer			Cancer				new to accord with NHSE V13
	Autologous Chondrocyte implantation	N				Articular cartilage defect				new to accord with NHSE V13
	Azathioprine	N	Immunosuppressants			Transplant immunosuppression only			New patients only until formal repatriation agreed	
	Bendamustine	N / CDF	Cancer			Cancer				
	Blinatumomab	N	Cancer			Cancer				new to accord with NHSE V13
	Brentuximab	N / CDF	Cancer			Cancer				
	Cabazitaxel	N	Cancer			Cancer				
	Cabozantinib	N / CDF	Cancer			Cancer				
	Carfilzomib	N	Cancer			Cancer				new to accord with NHSE V13
	Chemotherapy	N / CDF	Cancer			Cancer				Consult NHSE guidance / spreadsheet for individual drugs
	Ciclosporin	N	Immunosuppressants			Transplant immunosuppression only			New patients only until formal repatriation agreed	

										only as per NICE TA117 [i.e. dialysis patients]; otherwise is in Tariff. See Specialist Services Manual.
	Cinacalcet	N	Hypercalcaemia and hypercalciuria			Hyperparathyroidism - dialysis patients only				
	Clofarabine	CDF	Cancer			Cancer				
	Colestilan	N	Drugs for mineral bone disorders			Adult renal dialysis only				
	Daratumumab	CDF				Cancer				new to accord with NHSE V13
	Darbepoetin	N	Erythropoetins			Dialysis-induced anaemia				only as per NICE CG 114
	Epoetin (all variants)	N	Erythropoetins			Dialysis-induced anaemia				only as per NICE CG 114
	Eribulin	N / CDF	Cancer			Cancer				
	Etelcalcetide	N	Drugs for mineral bone disorders			Hyperparathyroidism - dialysis patients only				new to accord with NHSE V13
	Factor X (Cogadex)	N	Blood related products			Hereditary Factor X deficiency				new to accord with NHSE V12
	Ibrutinib	N / CDF	Protein kinase inhibitors			Cancer				
	Idelalisib	N	Protein kinase inhibitors			Cancer				
	Ipilimumab	N	Cancer			Cancer				
	Lanthanum	N	Phosphate binding agents			Adult renal dialysis only				
	Lenvatinib	N	Protein kinase inhibitors							
	Mesenchymal stem cells (e.g. Prochymal®)	N				Acute GvHD and other indications (BCSH)				
	Mycophenolate mofetil	N	Immunosuppressants			Transplant immunosuppression only			New patients only until formal repatriation agreed	
	Mycophenolic acid	N	Immunosuppressants			Transplant immunosuppression only			New patients only until formal repatriation agreed	
	Nelarabine	CDF	Cancer			Cancer				
	Nivolumab	N / CDF	Cancer			Cancer				
	Obinutuzumab	N / CDF	Cancer			Cancer				
	Olaparib	N	Cancer			Cancer				
	Olartumumab	CDF	Cancer			Cancer				
	Osimertinib	CDF	Cancer			Cancer				
	Palbociclib	N	Cancer			Cancer				
	Panitumumab	N	Cancer			Cancer				
	Panobinostat	N	Cancer			Cancer				
	Pegaspargase	N	Cancer			Cancer				
	Pegylated liposomal doxorubicin	N / CDF	Cancer			Cancer				
	Pemetrexed	N / CDF	Cancer			Cancer				
	Peptide receptor radionucleotide therapy	CDF	Cancer			Cancer				
	Pertuzumab	N	Cancer			Cancer				
	Pixantrone	N	Cancer			Cancer				
	Pomalidomide	CDF	Cancer			Cancer				
	Ponatinib	N*	Cancer			Cancer				
	Protein kinase inhibitors	N				Endocrinology; non-malignant conditions				
	Radium-223 dichloride	N / CDF	Cancer			Cancer				
	Ramucirumab	N	Cancer			Cancer				
	Ribociclib	N	Cancer			Cancer				
	Sevelamer	N	Phosphate binding agents			Adult renal dialysis only				

	Sirolimus	N	Immunosuppressants			Transplant immunosuppression only		New patients only until formal repatriation agreed	
	Strimvelis	N	ATMP			Adenosine deaminase deficiency - severe combined immunodeficiency			
	Tacrolimus	N	Immunosuppressants			Transplant immunosuppression only		New patients only until formal repatriation agreed	
	Talimogene laherparepvec	N	Cancer			Cancer			
	Temozolomide	N	Cancer			Endocrinology; non-malignant conditions			
	Tivozanib	CDF	Cancer			Cancer			
	Trabectedin	N	Antineoplastic drugs			Cancer			
	Trastuzumab	N	Cancer			Cancer			
	Trastuzumab emtansine	N	Cancer			Cancer			
	Trifluridine + tipiracil	N	Cancer			Cancer			
	Venetoclax	CDF	Cancer			Cancer			

Notes:

- Treatment of severe manifestations of some diseases is NCB commissioned e.g. Severe and / or fistulating Crohn's. Lanreotide / octreotide are CCG commissioned for non-cancer uses
- CCGs commission for all patients with autoimmune rheumatic diseases or rare arthropathies where the diagnosis is already established and the manifestations are well-controlled by conventional management and the patient and the rheumatologist are satisfied with treatment response and progress of the disease.
- Recommendations for cancer chemotherapy are to be excluded from 1/4/13. However, non-chemotherapy indications for the following will be CCG commissioned *if* use relates to a non-NHSE service: cladribine, lenalidomide, thalidomide, rilonacept, azacitidine, bevacizumab, bortezomib, cetuximab, protein kinase inhibitors, alemtuzumab.
- Drugs for which NHS England is the Commissioner are not necessarily *routinely* commissioned.
- Many drugs for which NHS England is the Commissioner are only commissioned by NHSE when from Specialist Centres; funding for requests outside of specialist centres would fall to CCGs.

For information: [reference A Strategic Framework for Intestinal Failure and Home Parenteral Nutrition Services for Adults in England. National Commissioning Group for Highly Specialised Services April 2008]

Type I – this type of Intestinal Failure is short-term, self limiting and often peri-operative in nature. Type I Intestinal Failure is common and these patients are managed successfully in a multitude of healthcare settings, especially surgical wards, including all units which perform major, particularly abdominal surgery. Some patients on high dependency units (HDU) and intensive care units (ICU) will also fall into this category.

Type II – Type II IF occurs in metabolically unstable patients in hospital and requires prolonged parenteral nutrition over periods of weeks or months. It is often associated with sepsis, and may be associated with renal impairment. These patients often need the facilities of an Intensive Care or High Dependency Unit for some or much of their stay in hospital. This type of IF is rarer and needs to be managed by a multi-professional specialist intestinal failure team. Effective management of Type II IF can reduce the likelihood of the development of Type III Intestinal Failure.

Type III – Type III is a chronic condition requiring long term parenteral feeding. The patient is characteristically metabolically stable but cannot maintain his or her nutrition adequately by absorbing food or nutrients via the intestinal tract. These are, in the main, the group of patients for which Home Parenteral Nutrition (HPN) is indicated.